<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Breast Cancer Res</journal-id><journal-title>Breast Cancer Research : BCR</journal-title><issn pub-type="ppub">1465-5411</issn><issn pub-type="epub">1465-542X</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">bcr2327</article-id><article-id pub-id-type="pmid">19549328</article-id><article-id pub-id-type="doi">10.1186/bcr2327</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Expression of FOXA1 and GATA-3 in breast cancer: the prognostic significance in hormone receptor-negative tumours</article-title></title-group><contrib-group><contrib id="A1" contrib-type="author"><name><surname>Albergaria</surname><given-names>Andr&#x000e9;</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>aalbergaria@ipatimup.pt</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Paredes</surname><given-names>Joana</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>jparedes@ipatimup.pt</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Sousa</surname><given-names>B&#x000e1;rbara</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>bsousa@ipatimup.pt</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Milanezi</surname><given-names>Fernanda</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>mmilanezi@ipatimup.pt</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Carneiro</surname><given-names>V&#x000ed;tor</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>gvcarneiro@gmail.com</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Bastos</surname><given-names>Joana</given-names></name><xref ref-type="aff" rid="I4">4</xref><xref ref-type="aff" rid="I5">5</xref><email>joanalbastos@gmail.com</email></contrib><contrib id="A7" contrib-type="author"><name><surname>Costa</surname><given-names>Sandra</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>sandracosta@ecsaude.uminho.pt</email></contrib><contrib id="A8" contrib-type="author"><name><surname>Vieira</surname><given-names>Daniella</given-names></name><xref ref-type="aff" rid="I6">6</xref><email>daniellavieira.hu@gmail.com</email></contrib><contrib id="A9" contrib-type="author"><name><surname>Lopes</surname><given-names>Nair</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>nlopes@ipatimup.pt</email></contrib><contrib id="A10" contrib-type="author"><name><surname>Lam</surname><given-names>Eric W</given-names></name><xref ref-type="aff" rid="I7">7</xref><email>eric.lam@imperial.ac.uk</email></contrib><contrib id="A11" contrib-type="author"><name><surname>Lunet</surname><given-names>Nuno</given-names></name><xref ref-type="aff" rid="I4">4</xref><xref ref-type="aff" rid="I5">5</xref><email>nlunet@med.up.pt</email></contrib><contrib id="A12" corresp="yes" contrib-type="author"><name><surname>Schmitt</surname><given-names>Fernando</given-names></name><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I8">8</xref><email>fschmitt@ipatimup.pt</email></contrib></contrib-group><aff id="I1"><label>1</label>Development Domain, Institute of Life and Health Sciences (ICVS), School of Health Sciences of Minho University &#x02013; Campus de Gualtar, Braga 4710-057, Portugal</aff><aff id="I2"><label>2</label>Cancer Genetics Group, Institute of Molecular Pathology and Immunology of Porto University (IPATIMUP), Rua Dr Roberto Frias s/n, Porto 4200-465, Portugal</aff><aff id="I3"><label>3</label>Department of Pathology of Hospital of Divino Esp&#x000ed;rito Santo, Rua da Grotinha, Ponta Delgada 9500-370, Portugal</aff><aff id="I4"><label>4</label>Department of Hygiene and Epidemiology, University of Porto Medical School, Alameda Prof. Hern&#x000e2;ni Monteiro, Porto 4200-319, Portugal</aff><aff id="I5"><label>5</label>Institute of Public Health of the University of Porto (ISPUP), Pra&#x000e7;a Gomes Teixeira s/n, Porto 4099-002, Portugal</aff><aff id="I6"><label>6</label>Department of Pathology, Federal University of Santa Catarina, Campus Reitor Jo&#x000e3;o David Ferreira Lima, Florian&#x000f3;polis, Santa Catarina CEP 88040-970, Brazil</aff><aff id="I7"><label>7</label>Department of Oncology, Cancer Research UK Laboratories, MRC Cyclotron Building, Imperial College of London, Hammersmith Hospital, Du Cane Road, London W12 0HS, UK</aff><aff id="I8"><label>8</label>Department of Pathology, Medical Faculty of University of Porto, Alameda Prof. Hern&#x000e2;ni Monteiro, Porto 4200-319, Portugal</aff><pub-date pub-type="ppub"><year>2009</year></pub-date><pub-date pub-type="epub"><day>23</day><month>6</month><year>2009</year></pub-date><volume>11</volume><issue>3</issue><fpage>R40</fpage><lpage>R40</lpage><ext-link ext-link-type="uri" xlink:href="http://breast-cancer-research.com/content/11/3/R40"/><history><date date-type="received"><day>5</day><month>1</month><year>2009</year></date><date date-type="rev-request"><day>9</day><month>2</month><year>2009</year></date><date date-type="rev-recd"><day>26</day><month>5</month><year>2009</year></date><date date-type="accepted"><day>23</day><month>6</month><year>2009</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2009 Albergaria et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2009</copyright-year><copyright-holder>Albergaria et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an open access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Albergaria Andr&#x000e9; aalbergaria@ipatimup.pt </dc:author><dc:title> Expression of FOXA1 and GATA-3 in breast cancer: the prognostic significance in hormone receptor-negative tumours </dc:title><dc:date>2009</dc:date><dcterms:bibliographicCitation>Breast Cancer Research 11(3): R40-. (2009)</dcterms:bibliographicCitation><dc:identifier type="sici">1465-5411(2009)11:3&#x0003c;R40&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1465-5411</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Introduction</title><p>The expression of additional genes, other than oestrogen receptor (ER), may be important to the hormone-responsive phenotype of breast cancer. Microarray analyses have revealed that forkhead box A1 (FOXA1) and GATA binding protein 3 (GATA-3) are expressed in close association with ER&#x003b1;, both encoding for transcription factors with a potential involvement in the ER&#x003b1;-mediated action in breast cancer. The purpose of this study was to explore if the expression of FOXA1 and GATA-3 may provide an opportunity to stratify subsets of patients that could have better outcome, among the ER&#x003b1;-negative/poor prognosis breast cancer group.</p></sec><sec sec-type="methods"><title>Methods</title><p>We evaluate FOXA1 and GATA-3 expression in 249 breast carcinomas by immunohistochemistry, associating it with breast cancer molecular markers, clinicopathological features and patient's survival. The clinicopathological features and immunohistochemical markers of the tumours were compared using the chi-square test and ANOVA. Disease-free survival was analysed through Kaplan&#x02013;Meier survival curves and Cox regression.</p></sec><sec><title>Results</title><p>FOXA1 expression was demonstrated in 42% of invasive carcinomas, while GATA-3 was detected in 48% of the cases. FOXA1 expression was inversely associated with tumour size, Nottingham Prognostic Index, histological grade, lymph vascular invasion, lymph node stage and human epidermal growth factor receptor-2 (HER-2) overexpression, while GATA-3 expression showed inverse association with histological grade and HER-2. Both FOXA1 and GATA-3 were directly associated with ER&#x003b1; and progesterone receptor. Among FOXA1-positive tumours, 83.1% are comprised in the luminal A subtype, similar to GATA-3 where 87.7% of positive tumours were classified within this molecular subtype. In the subset of ER&#x003b1;-negative patients, those who were FOXA1-negative had a 3.61-fold increased risk of breast cancer recurrence when compared with the FOXA1-positive.</p></sec><sec><title>Conclusions</title><p>FOXA1 was a significant predictor of good outcome in breast cancer, whereas GATA-3 was an important luminal marker. The expression of FOXA1 may be used for risk stratification among ER&#x003b1;-negative patients.</p></sec></abstract></article-meta></front><body><sec><title>Introduction</title><p>The expression of oestrogen receptor (ER) is an important prognostic and predictive factor in breast cancer and has relevant implications for the biology of this type of carcinomas. Patients with tumours that express ER have a longer disease-free interval and overall survival than patients with tumours lacking ER expression [<xref ref-type="bibr" rid="B1">1</xref>].</p><p>According to international treatment guidelines for early breast cancer, patients with ER&#x003b1; and/or progesterone receptor (PR) expression should receive an adjuvant endocrine therapy, since their expression is associated with higher response rates to anti-hormonal treatment [<xref ref-type="bibr" rid="B2">2</xref>]. However, the association between ER&#x003b1; expression and hormonal responsiveness is far from perfect, since approximately 30% of ER-positive tumours do not respond to hormonal treatment and 5 to 15% of ER-negative tumours curiously respond to endocrine therapy [<xref ref-type="bibr" rid="B3">3</xref>].</p><p>In order to overcome and explore this unpredictable breast tumour behaviour, numerous studies, based on cDNA microarrays, have shown that the gene expression profile in breast cancer can provide molecular phenotypes that identify distinct tumour subclasses [<xref ref-type="bibr" rid="B4">4</xref>-<xref ref-type="bibr" rid="B6">6</xref>], patient survival prediction [<xref ref-type="bibr" rid="B5">5</xref>-<xref ref-type="bibr" rid="B7">7</xref>], and differences in tumour biology or clinical features. The molecular classification of breast cancers distinguishes three major subtypes: the ER-positive/luminal-like subtype, a gene expression cluster characteristic of the luminal cells and anchored by a cluster of transcription factors that include ER; the basal-like subtype, comprising tumours that express basal cell markers (namely keratin 5, keratin 14, integrin &#x003b2;<sub>4 </sub>and laminin); and the human epidermal growth factor receptor-2 (HER-2)-overexpressing subtype, usually associated with gene amplification of the HER-2 proto-oncogene and high expression of several genes in the ERBB2 amplicon at 17q22.24 [<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B8">8</xref>]. These studies have largely contributed to understanding the complex behaviour of certain types of breast cancer, including the ones that respond better to endocrine therapies, regardless of ER expression.</p><p>Oestrogen plays an important role in the regulation of growth, proliferation and differentiation of mammary epithelium. The action of oestrogen is mediated through the ER, which functions as an oestrogen-activated transcription factor. The expression of an additional set of genes that is not part of the canonical oestradiol-response pathway may also be essential in clarifying the hormone-responsive phenotype, since intrinsic differences in the list of transcription factors bound to the <italic>ER </italic>gene promoter have been described [<xref ref-type="bibr" rid="B9">9</xref>].</p><p>Additionally, the distinct behaviour observed between ER-positive luminal subtypes A and B (a subgroup of tumours with low to moderate expression of the luminal-specific genes including the ER cluster) may in part be due to the influence of additional factors, including transcriptional factors, co-activators and co-repressors modulating ER activity [<xref ref-type="bibr" rid="B10">10</xref>], which can also be explored towards a therapeutic purpose.</p><p>In 2004 Lacroix and Leclercq compiled considerable extensive data describing the strong association and cross-talk between ER&#x003b1;, forkhead box A1 (FOXA1) and GATA binding protein 3 (GATA-3) [<xref ref-type="bibr" rid="B11">11</xref>]. In most of these studies, GATA-3 and FOXA1 have been highlighted within the ER&#x003b1; pathway in the luminal A subtype [<xref ref-type="bibr" rid="B4">4</xref>-<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B12">12</xref>]; FOXA1, a forkhead family transcription factor, has been receiving considerable attention, since it interacts with <italic>cis</italic>-regulatory regions of heterochromatin, enhancing the interaction of ER&#x003b1; with DNA [<xref ref-type="bibr" rid="B13">13</xref>]. Carroll and colleagues recently described several robust data demonstrating the requirement of FOXA1 for optimal expression of nearly 50% of ER&#x003b1;-regulated genes and oestrogen-induced proliferation [<xref ref-type="bibr" rid="B13">13</xref>,<xref ref-type="bibr" rid="B14">14</xref>].</p><p>FOXA1 is expressed in the liver, pancreas, bladder, prostate, colon and lung, as well as in the mammary gland, and can bind to the promoters of more than 100 genes associated with metabolic processes, regulation of signalling pathways and cell cycle [<xref ref-type="bibr" rid="B15">15</xref>-<xref ref-type="bibr" rid="B17">17</xref>]. Some studies have shown that FOXA1 can act either as a growth stimulator/activator or as a repressor. As a stimulator, FOXA1 binds to chromatinised DNA and opens the chromatin, enhancing binding of ER&#x003b1; to its target genes [<xref ref-type="bibr" rid="B18">18</xref>] &#x02013; which suggests a growth-promoting role for this forkhead protein [<xref ref-type="bibr" rid="B14">14</xref>,<xref ref-type="bibr" rid="B18">18</xref>]. In breast cancer, however, FOXA1 overexpression can also block the metastatic progression by influencing the expression of the BRCA1-associated cell-cycle inhibitor p27 and promoting E-cadherin expression [<xref ref-type="bibr" rid="B19">19</xref>,<xref ref-type="bibr" rid="B20">20</xref>]. Recent studies also suggest FOXA1 as a favourable prognostic factor in breast cancer, with potential relevance in the subclassification of luminal/ER-positive tumours into two subgroups with different biological behaviour and prognosis, the luminal A and the luminal B [<xref ref-type="bibr" rid="B5">5</xref>].</p><p>FOXA1 and ER&#x003b1; have been explored as potential participants involved in mammary tumours together with another gene, GATA-3 [<xref ref-type="bibr" rid="B21">21</xref>,<xref ref-type="bibr" rid="B22">22</xref>], which regulates the lineage determination and differentiation of many cells types. In the breast, GATA-3 plays a central role in luminal epithelia differentiation and the subsequent formation of the ductal tree of differentiated epithelial cells [<xref ref-type="bibr" rid="B23">23</xref>], suggesting that this protein might be involved in breast tumorigenesis [<xref ref-type="bibr" rid="B24">24</xref>].</p><p>Meta-analysis of four microarray datasets indicated that GATA-3 was a strong predictor of clinical outcome in breast tumours and is among the best predictors of ER-positive status [<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B25">25</xref>-<xref ref-type="bibr" rid="B27">27</xref>]. Among all of the molecular subgroups of breast cancer, the luminal A subtype has a relatively favourable outcome and the highest GATA-3 and ER&#x003b1; expression levels, compared with luminal B and basal-like breast carcinomas [<xref ref-type="bibr" rid="B24">24</xref>].</p><p>As a result of all of these extensive studies underlying GATA-3 and ER&#x003b1; in mammary epithelia, it has been clear that GATA-3 is a crucial regulator of tumour differentiation and suppressor of tumour dissemination [<xref ref-type="bibr" rid="B22">22</xref>]. It has been also suggested that these functions in mammary luminal cells may be linked by transcriptional regulators, whereas FOXA1 appears as a candidate gene, which is necessary for the transcriptional activity of ER&#x003b1; and its binding to oestrogen-responsive elements in target gene promoters [<xref ref-type="bibr" rid="B13">13</xref>,<xref ref-type="bibr" rid="B18">18</xref>]. As FOXA1 may also be a downstream effector of GATA-3, it may be a bridge between GATA-3 and ER pathways [<xref ref-type="bibr" rid="B22">22</xref>], controlling and regulating the biology of luminal mammary cells, breast cancer progression and behaviour.</p><p>Based on this intricate and functional complex between FOXA1 and GATA-3 in breast cancer biology, it is reasonable to consider that these transcription factors, in addition to ER&#x003b1;, are important in establishing and clarifying the hormone-responsive phenotype and prognosis in breast cancer. This gene set may therefore be used as a diagnostic tool for more accurate determination of ER&#x003b1; status, in the decision on endocrine therapeutic strategies, as well as in the assessment of breast cancer patient's outcome.</p><p>In the present study we provide an immunohistochemical approach studying FOXA1 and GATA-3 expression, in order to predict the tumour behaviour of breast cancer patients. In the whole series, we verified that patients harbouring FOXA1-positive tumours show a better disease-free survival. Interestingly, and for the first time, we also found the same power of risk stratification among the ER&#x003b1;-negative breast cancer patients, demonstrating the clinical importance of this biomarker in breast cancer molecular classification and prognosis. These results show that FOXA1 and ER&#x003b1; should be used together in order to subclassify breast carcinomas and to predict the outcome of breast cancer patients.</p></sec><sec sec-type="materials|methods"><title>Materials and methods</title><sec><title>Patient selection</title><p>A series of 249 cases of primary operable invasive breast carcinomas were retrieved from the files of the Department of Pathology, Hospital do Divino Esp&#x000ed;rito Santo, Azores, Portugal and from the Federal University of Santa Catarina, Florianopolis &#x02013; SC, Brazil. These samples were obtained from patients with age ranging from 30 to 89 years. All of the formalin-fixed paraffin-embedded histological sections were reviewed by three pathologists (VC, FS and FM) and the diagnoses were confirmed as follows: 208 invasive ductal carcinomas, seven invasive lobular carcinomas, three mixed breast carcinomas, three tubular breast carcinomas, eight medullary breast carcinomas and 20 invasive breast carcinomas of other special histological types. These tumours have been fully characterized for clinical and pathological features &#x02013; namely, age, tumour size, histological type, lymph nodes invasion, tumour grade, Nottingham Prognostic Index, ER&#x003b1;, PR and HER-2 status. The patients' clinical and pathological characteristics are summarized in Table <xref ref-type="table" rid="T1">1</xref>.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Patient characteristics and tumour parameters</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left">Variable</td><td align="left">Data</td></tr></thead><tbody><tr><td align="left">Age at diagnosis (years)</td><td></td></tr><tr><td align="left">&#x02003;Mean and standard deviation</td><td align="left">57 &#x000b1; 14.2</td></tr><tr><td align="left">&#x02003;Range</td><td align="left">59 (minimum 30; maximum 89)</td></tr><tr><td align="left">Tumour size (mm)</td><td></td></tr><tr><td align="left">&#x02003;Mean and standard deviation</td><td align="left">32 &#x000b1; 21 mm</td></tr><tr><td align="left">&#x02003;Range</td><td align="left">145 (minimum 5; maximum 150)</td></tr><tr><td align="left">Lymphovascular invasion</td><td></td></tr><tr><td align="left">&#x02003;Present</td><td align="left">111 (44.6)</td></tr><tr><td align="left">&#x02003;Absent</td><td align="left">111 (44.6)</td></tr><tr><td align="left">&#x02003;Not assessed</td><td align="left">27 (10.8)</td></tr><tr><td align="left">Lymph node sage</td><td></td></tr><tr><td align="left">&#x02003;Negative</td><td align="left">111 (44.6)</td></tr><tr><td align="left">&#x02003;1 to 3 lymph nodes</td><td align="left">57 (22.9)</td></tr><tr><td align="left">&#x02003;&#x0003e;3 lymph nodes</td><td align="left">54 (21.7)</td></tr><tr><td align="left">&#x02003;Not assessed</td><td align="left">27 (10.8)</td></tr><tr><td align="left">Tumour grade</td><td></td></tr><tr><td align="left">&#x02003;Grade I</td><td align="left">51 (20.5)</td></tr><tr><td align="left">&#x02003;Grade II</td><td align="left">116 (46.6)</td></tr><tr><td align="left">&#x02003;Grade III</td><td align="left">82 (32.9)</td></tr><tr><td align="left">Histology</td><td></td></tr><tr><td align="left">&#x02003;Invasive ductal carcinoma (not otherwise specified)</td><td align="left">208 (83.5)</td></tr><tr><td align="left">&#x02003;Invasive lobular carcinoma</td><td align="left">7 (2.8)</td></tr><tr><td align="left">&#x02003;Mixed</td><td align="left">3 (1.2)</td></tr><tr><td align="left">&#x02003;Tubular</td><td align="left">3 (1.2)</td></tr><tr><td align="left">&#x02003;Medullary</td><td align="left">8 (3.3)</td></tr><tr><td align="left">&#x02003;Other special types</td><td align="left">20 (8.0)</td></tr><tr><td align="left">Nottingham Prognostic Index</td><td></td></tr><tr><td align="left">&#x02003;&#x0003c;3.4</td><td align="left">46 (18.5)</td></tr><tr><td align="left">&#x02003;3.4 to 5.4</td><td align="left">106 (42.6)</td></tr><tr><td align="left">&#x02003;&#x0003e;5.4</td><td align="left">55 (22.0)</td></tr><tr><td align="left">&#x02003;Not assessed</td><td align="left">42 (16.9)</td></tr><tr><td align="left">Oestrogen receptor-&#x003b1; status</td><td></td></tr><tr><td align="left">&#x02003;Positive</td><td align="left">141 (56.6)</td></tr><tr><td align="left">&#x02003;Negative</td><td align="left">107 (43.0)</td></tr><tr><td align="left">&#x02003;Unknown</td><td align="left">1 (0.4)</td></tr><tr><td align="left">Progesterone receptor status</td><td></td></tr><tr><td align="left">&#x02003;Positive</td><td align="left">89 (35.8)</td></tr><tr><td align="left">&#x02003;Negative</td><td align="left">154 (61.8)</td></tr><tr><td align="left">&#x02003;Unknown</td><td align="left">6 (2.4)</td></tr><tr><td align="left">Human epidermal growth factor receptor 2 status</td><td></td></tr><tr><td align="left">&#x02003;Positive</td><td align="left">42 (16.9)</td></tr><tr><td align="left">&#x02003;Negative</td><td align="left">201 (80.7)</td></tr><tr><td align="left">&#x02003;Unknown</td><td align="left">6 (2.4)</td></tr></tbody></table><table-wrap-foot><p>Data presented as <italic>n </italic>(%) unless stated otherwise.</p></table-wrap-foot></table-wrap><p>Follow-up information was available for 218 cases, ranging from a minimum of 2 months to a maximum of 129 months (median 32 months). The disease-free survival data interval was evaluated and defined as the time from the date of surgery to the date of breast-cancer-derived relapse/metastasis. Owing to the short follow-up of the studied series and the consequent limited number of death events, overall survival was not analysed.</p><p>The present study was conducted under the national regulative law for the usage of biological specimens from tumour banks, where the samples are exclusively available for research purposes in the case of retrospective studies.</p></sec><sec><title>Tissue microarray construction and immunohistochemical analysis</title><p>Representative areas of different lesions were carefully selected on haematoxylin and eosin-stained sections and were marked on individual paraffin blocks. Two tissue cores (2 mm in diameter) were obtained from each selected specimen and were precisely deposited into a recipient paraffin block using a tissue microarray workstation (tissue microarray builder ab1802; Abcam, Cambridge, UK) as described elsewhere [<xref ref-type="bibr" rid="B28">28</xref>,<xref ref-type="bibr" rid="B29">29</xref>]. In each tissue microarray block, non-neoplastic breast tissue cores were also included as controls.</p><p>Immunohistochemistry was performed in 3 &#x003bc;m formalin-fixed, paraffin-embedded sections. Expression for the most commonly used breast cancer markers &#x02013; namely, HER-2, ER, PR, P-cadherin, epidermal growth factor receptor (EGFR), vimentin and basal cytokeratins (CK5, CK14) &#x02013; was assessed. The immunohistochemistry technique was performed using an Envision Detection System (DAKO Cytomation Envision System HRP; DAKO Corporation, Carpinteria, CA, USA) or the classical streptavidin &#x02013; avidin &#x02013; biotin complex method according to the manufacturer's instructions. Imunohistochemistry assay conditions and antibodies specifications were based on previously published studies from our group [<xref ref-type="bibr" rid="B28">28</xref>-<xref ref-type="bibr" rid="B30">30</xref>]. Immunoreactivity for ER&#x003b1;, PR, P-cadherin, CK5, CK14, EGFR, vimentin and HER-2 was classified by estimating the percentage of tumour cells showing characteristic staining, in accordance with previous work [<xref ref-type="bibr" rid="B28">28</xref>-<xref ref-type="bibr" rid="B30">30</xref>].</p><p>Expression of FOXA1 was analysed using a mouse monoclonal antibody (clone 2F83, ab40868; AbCam), as well as GATA-3 expression (clone H-63-31, Sc-268; Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA). Sections were deparaffinized with xylene and rehydrated in a series of decreasing concentration of ethanol solutions. Heat-induced epitope retrieval was carried out in 10 mM citrate buffer (sodium citrate) (pH 6) or in 1 mM ethylenediamine tetraacetic acid buffer (pH 8) (LabVision Corporation, Fremont, CA, USA), in a 98&#x000b0;C water bath, for 14 and 20 minutes for FOXA1 and GATA-3, respectively. After cooling retrieval solutions for at least 30 minutes at room temperature, the slides were treated for 10 minutes with 3% H<sub>2</sub>O<sub>2 </sub>in methanol, in order to block endogenous peroxidase. Slides were incubated with monoclonal antibodies for FOXA1 (1:450) and GATA-3 (1:100) for 2 hours at room temperature and were labelled with the Envision Detection System from DAKO. Colour reaction product was developed with 3,3'-diaminobenzidine, tetrahydrochloride (DAB plus; DAKO Glostrup, Denmark) as a substrate, and nuclear contrast was achieved with haematoxylin/ammoniacal water counterstaining. Formalin-fixed, paraffin-embedded sections from normal breast gland were used as FOXA1 and GATA-3 positive controls. Negative controls were performed by replacing the primary antibody with PBS/nonimmune mouse serum.</p><p>The scoring method used for FOXA1 and GATA-3 expression was based on a semi-quantitative scoring system previously described by Thorat and colleagues, where the cutoff value for FOXA1 positivity was validated [<xref ref-type="bibr" rid="B31">31</xref>]. In this scoring system, the percentage of staining was categorized as: 0 = no nuclear expression; 1 = 1 to 10% positive tumour nuclei; 2 = 11 to 20%; and so on until a maximum score of 10 = 91 to 100% positive tumour nuclei. The intensity was scored as: 1+ = weak staining; 2+ = moderate staining; and 3+ = strong staining. The numeric final score was generated by the multiplication product of percentage and intensity of nuclear expression (scoring = percentage &#x000d7; intensity) [<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B32">32</xref>]. Based on this semiquantitative scoring system, scores between 0 and 3 were classified as negative, and scores &#x02265; 4 to a maximum of 30 were considered positive.</p></sec><sec><title>Statistical analysis</title><p>Statistical analysis was performed using Stata&#x02122;, version 9.2 software (StataCorp, College Station, TX, USA). Continuous variables were presented as the mean &#x000b1; standard deviation, and categorical variables were presented as the number (percentage). The clinicopathological features and immunohistochemical markers of the tumours were compared across groups of expression of FOXA1 and GATA-3 using analysis of variance and the chi-square test, respectively, for continuous and categorical variables.</p><p>Survival curves were estimated by the Kaplan &#x02013; Meier method using the log-rank test to assess significant differences for disease-free patient survival. A maximum cutoff value of 60 months (5 years) was considered, since this is the expected clinical time for breast cancer recurrence. Cox regression models were fitted to estimate hazard ratios and the corresponding 95% confidence interval for the classical prognostic factors, FOXA1 and GATA-3. In all analyses, a significant level of 5% was considered.</p></sec></sec><sec><title>Results</title><sec><title>FOXA1 and GATA-3 expression in normal and malignant breast tissues</title><p>From the total 249 cases, only cases with clear and restricted nuclear expression for FOXA1 and GATA-3 were selected for immunohistochemistry classification. Three representative cases were selected to build a panel, illustrated in Figure <xref ref-type="fig" rid="F1">1</xref>, comprising a classical example of the following molecular subtypes of breast cancer: luminal A subtype (Figure <xref ref-type="fig" rid="F1">1</xref>, L1 to L7), basal-like subtype (Figure <xref ref-type="fig" rid="F1">1</xref>, B1 to B7) and HER-2-overexpressing subtype (Figure <xref ref-type="fig" rid="F1">1</xref>, H1 to H7). Strong immunoexpression of FOXA1 and GATA-3 in the nuclei of malignant cells, as well as in some luminal epithelial cells from adjacent normal ducts, is shown in Figure <xref ref-type="fig" rid="F1">1</xref> (L3 and L4). FOXA1 was positive (score &#x02265; 4) in the nuclei of 42% (93 out of 224) of the invasive carcinomas, while GATA-3 was detected in 48% (97 out of 204) of the cases.</p><fig position="float" id="F1"><label>Figure 1</label><caption><p>Immunohistochemistry panel showing differential expression pattern of FOXA1 and GATA-3. An example of luminal A <bold>(L1 to L7)</bold>, basal-like <bold>(B1 to B7) </bold>and human epidermal growth factor receptor 2 (HER-2)-overexpressing <bold>(H1 to H7) </bold>invasive breast tumours. Expression of the most commonly used breast cancer markers is also illustrated for comparison with the forkhead box A1 (FOXA1) and GATA binding protein 3 (GATA-3) expression. (L1, B1, H1) Haematoxylin-eosin stainings from each of the selected core cases. (L3, L4) Strong and restricted nuclear expression of FOXA1 and GATA-3 in the normal breast duct (internal control) and in the luminal A invasive tumour (grade II). (B3, B4) Negative expression of FOXA1 and GATA-3 in basal subtype tumour (grade III). (H3, H4) HER-2-overexpressing tumour showing negativity for FOXA1 and GATA-3 expression (grade III). All microscopy images are at 40&#x000d7; magnification. ER, oestrogen receptor; P-CAD, P-cadherin; CK, cytokeratin.</p></caption><graphic xlink:href="bcr2327-1"/></fig></sec><sec><title>Association between FOXA1 and GATA-3 expression and clinicopathological features and biological markers</title><p>The expression of FOXA1 was inversely associated with tumour size (<italic>P </italic>= 0.005), Nottingham Prognostic Index (<italic>P </italic>= 0.002), histological grade (<italic>P </italic>= 0.001), vascular invasion (<italic>P </italic>= 0.012), lymph node stage (<italic>P </italic>= 0.022) and HER-2 overexpression (<italic>P </italic>= 0.017), and was directly associated with ER&#x003b1; expression (<italic>P </italic>&#x0003c; 0.0001) and PR expression (<italic>P </italic>&#x0003c; 0.0001). GATA-3 expression showed an inverse association with histological grade (<italic>P </italic>= 0.013) and HER-2 overexpression (<italic>P </italic>&#x0003c; 0.0001), and a direct association with ER&#x003b1; expression (<italic>P </italic>&#x0003c; 0.001) and PR expression (<italic>P </italic>&#x0003c; 0.001) (Table <xref ref-type="table" rid="T2">2</xref>).</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Association between FOXA1 and GATA3 expression and the clinicopathological features of the infiltrative breast carcinomas</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left">Variable</td><td align="left"><italic>N</italic></td><td align="left">FOXA1-negative (%)</td><td align="left">FOXA1-positive (%)</td><td align="left"><italic>P </italic>value</td><td align="left"><italic>n</italic></td><td align="left">GATA3-negative (%)</td><td align="left">GATA3-positive (%)</td><td align="left"><italic>P </italic>value</td></tr></thead><tbody><tr><td align="left">Tumour size (mm)</td><td align="left">209</td><td align="left">35.2 &#x000b1; 24.0 (126)</td><td align="left">26.8 &#x000b1; 15.7 (83)</td><td align="left">0.005</td><td align="left">191</td><td align="left">34.4 &#x000b1; 25.2 (100)</td><td align="left">28.6 &#x000b1; 16.7 (91)</td><td align="left">0.064</td></tr><tr><td align="left">Lymphovascular invasion</td><td align="left">203</td><td></td><td></td><td></td><td align="left">185</td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;Present</td><td align="left">97</td><td align="left">67 (69.1)</td><td align="left">30 (30.9)</td><td align="left">0.012</td><td align="left">92</td><td align="left">49 (53.3)</td><td align="left">43 (46.7)</td><td align="left">0.829</td></tr><tr><td align="left">&#x02003;Absent</td><td align="left">106</td><td align="left">55 (51.9)</td><td align="left">51 (48.1)</td><td></td><td align="left">93</td><td align="left">51 (54.8)</td><td align="left">42 (45.2)</td><td></td></tr><tr><td align="left">Lymph node stage</td><td align="left">203</td><td></td><td></td><td></td><td align="left">185</td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;Negative</td><td align="left">106</td><td align="left">55 (51.9)</td><td align="left">51 (48.1)</td><td align="left">0.022</td><td align="left">93</td><td align="left">51 (54.8)</td><td align="left">42 (45.2)</td><td align="left">0.166</td></tr><tr><td align="left">&#x02003;1 to 3 lymph nodes</td><td align="left">49</td><td align="left">31 (63.3)</td><td align="left">18 (36.7)</td><td></td><td align="left">46</td><td align="left">20 (43.5)</td><td align="left">26 (56.5)</td><td></td></tr><tr><td align="left">&#x02003;&#x0003e;3 lymph nodes</td><td align="left">48</td><td align="left">36 (75)</td><td align="left">12 (25)</td><td></td><td align="left">46</td><td align="left">29 (63)</td><td align="left">17 (37)</td><td></td></tr><tr><td align="left">Grade</td><td align="left">224</td><td></td><td></td><td></td><td align="left">204</td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;Grade I</td><td align="left">44</td><td align="left">25 (56.8)</td><td align="left">19 (43.2)</td><td align="left">0.001</td><td align="left">40</td><td align="left">24 (60)</td><td align="left">16 (40)</td><td align="left">0.013</td></tr><tr><td align="left">&#x02003;Grade II</td><td align="left">105</td><td align="left">50 (47.6)</td><td align="left">55 (52.4)</td><td></td><td align="left">96</td><td align="left">40 (41.7)</td><td align="left">56 (58.3)</td><td></td></tr><tr><td align="left">&#x02003;Grade III</td><td align="left">75</td><td align="left">56 (74.7)</td><td align="left">19 (25.3)</td><td></td><td align="left">68</td><td align="left">43 (63.2)</td><td align="left">25 (36.8)</td><td></td></tr><tr><td align="left">Histology</td><td align="left">224</td><td></td><td></td><td></td><td align="left">204</td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;IDC</td><td align="left">188</td><td align="left">113 (60.1)</td><td align="left">75 (39.9)</td><td align="left">0.119</td><td align="left">171</td><td align="left">91 (53.2)</td><td align="left">80 (46.8)</td><td align="left">0.104</td></tr><tr><td align="left">&#x02003;ILC</td><td align="left">6</td><td align="left">2 (33.3)</td><td align="left">4 (66.7)</td><td></td><td align="left">6</td><td align="left">0 (0)</td><td align="left">6 (100)</td><td></td></tr><tr><td align="left">&#x02003;Tubular</td><td align="left">1</td><td align="left">1 (100)</td><td align="left">0 (0)</td><td></td><td align="left">1</td><td align="left">0 (0)</td><td align="left">1 (100)</td><td></td></tr><tr><td align="left">&#x02003;Medullary</td><td align="left">7</td><td align="left">5 (71.4)</td><td align="left">2 (28.6)</td><td></td><td align="left">7</td><td align="left">5 (71.4)</td><td align="left">2 (28.6)</td><td></td></tr><tr><td align="left">&#x02003;Other</td><td align="left">19</td><td align="left">7 (36.8)</td><td align="left">12 (63.2)</td><td></td><td align="left">16</td><td align="left">9 (56.2)</td><td align="left">7 (43.8)</td><td></td></tr><tr><td align="left">&#x02003;Mixed</td><td align="left">3</td><td align="left">3 (100)</td><td align="left">0 (0)</td><td></td><td align="left">3</td><td align="left">2 (66.7)</td><td align="left">1 (33.3)</td><td></td></tr><tr><td align="left">Nottingham Prognostic Index</td><td align="left">190</td><td></td><td></td><td></td><td align="left">172</td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;&#x0003c;3.4</td><td align="left">44</td><td align="left">18 (40.9)</td><td align="left">26 (59.1)</td><td align="left">0.002</td><td align="left">40</td><td align="left">19 (47.5)</td><td align="left">21 (52.5)</td><td align="left">0.293</td></tr><tr><td align="left">&#x02003;3.4 to 5.4</td><td align="left">96</td><td align="left">59 (61.5)</td><td align="left">37 (38.5)</td><td></td><td align="left">86</td><td align="left">44 (51.2)</td><td align="left">42 (48.8)</td><td></td></tr><tr><td align="left">&#x02003;&#x0003e;5.4</td><td align="left">50</td><td align="left">38 (76)</td><td align="left">12 (24)</td><td></td><td align="left">46</td><td align="left">29 (63)</td><td align="left">17 (37)</td><td></td></tr><tr><td align="left">ER&#x003b1;</td><td align="left">224</td><td></td><td></td><td></td><td align="left">204</td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;Positive</td><td align="left">133</td><td align="left">60 (45.1)</td><td align="left">73 (54.9)</td><td align="left">&#x0003c;0.0001</td><td align="left">122</td><td align="left">41 (33.6)</td><td align="left">81 (66.4)</td><td align="left">&#x0003c;0.0001</td></tr><tr><td align="left">&#x02003;Negative</td><td align="left">91</td><td align="left">71 (78)</td><td align="left">20 (22)</td><td></td><td align="left">82</td><td align="left">66 (80.9)</td><td align="left">16 (19.5)</td><td></td></tr><tr><td align="left">PR</td><td align="left">223</td><td></td><td></td><td></td><td align="left">204</td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;Positive</td><td align="left">83</td><td align="left">33 (39.7)</td><td align="left">50 (60.3)</td><td align="left">&#x0003c;0.0001</td><td align="left">74</td><td align="left">22 (29.7)</td><td align="left">52 (70.3)</td><td align="left">&#x0003c;0.0001</td></tr><tr><td align="left">&#x02003;Negative</td><td align="left">140</td><td align="left">98 (70)</td><td align="left">42 (30)</td><td></td><td align="left">130</td><td align="left">85 (65.4)</td><td align="left">45 (34.6)</td><td></td></tr><tr><td align="left">HER-2</td><td align="left">220</td><td></td><td></td><td></td><td align="left">201</td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;Positive</td><td align="left">35</td><td align="left">27 (77.1)</td><td align="left">8 (22.9)</td><td align="left">0.017</td><td align="left">34</td><td align="left">29 (85.3)</td><td align="left">5 (14.7)</td><td align="left">&#x0003c;0.0001</td></tr><tr><td align="left">&#x02003;Negative</td><td align="left">185</td><td align="left">103 (55.7)</td><td align="left">82 (44.3)</td><td></td><td align="left">167</td><td align="left">77 (46.1)</td><td align="left">90 (53.9)</td><td></td></tr></tbody></table><table-wrap-foot><p>FOXA-1, forkhead box A1; GATA-3, GATA binding protein 3; IDC, invasive ductal carcinoma (not otherwise specified); ILC, invasive lobular carcinoma; ER&#x003b1;, oestrogen receptor; PR, progesterone receptor; HER-2, human epidermal growth factor receptor 2.</p></table-wrap-foot></table-wrap><p>When we compared the expression of FOXA1 and GATA-3 with the molecular subtype, we found that 83.1% and 87.7% of FOXA1 and GATA-3, respectively, were comprised in the luminal A subtype (<italic>P </italic>&#x0003c; 0.0001) (Table <xref ref-type="table" rid="T3">3</xref> and Figure <xref ref-type="fig" rid="F1">1</xref>, L1 to L7). Basal-like subtype tumours were negative for FOXA1 (Figure <xref ref-type="fig" rid="F1">1</xref>, B3) and for GATA-3 (Figure <xref ref-type="fig" rid="F1">1</xref>, B4) in 85.7% and 84.6% of the cases, respectively (Table <xref ref-type="table" rid="T3">3</xref>).</p><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Association between FOXA1 and GATA3 expression and the immunohistochemical markers in infiltrative breast carcinomas</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left">Variable</td><td align="left"><italic>N</italic></td><td align="left">FOXA1-negative (%)</td><td align="left">FOXA1-positive (%)</td><td align="left"><italic>P </italic>value</td><td align="left"><italic>n</italic></td><td align="left">GATA3-negative (%)</td><td align="left">GATA3-positive (%)</td><td align="left"><italic>P </italic>value</td></tr></thead><tbody><tr><td align="left">EGFR</td><td align="left">223</td><td></td><td></td><td></td><td align="left">203</td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;Positive</td><td align="left">13</td><td align="left">10 (7.6)</td><td align="left">3 (3.3)</td><td align="left">0.171</td><td align="left">11</td><td align="left">11 (10.4)</td><td align="left">0 (0)</td><td align="left">0.001</td></tr><tr><td align="left">&#x02003;Negative</td><td align="left">210</td><td align="left">121 (92.4)</td><td align="left">89 (96.7)</td><td></td><td align="left">192</td><td align="left">95 (89.6)</td><td align="left">97 (100)</td><td></td></tr><tr><td align="left">P-cadherin</td><td align="left">220</td><td></td><td></td><td></td><td align="left">202</td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;Positive</td><td align="left">75</td><td align="left">53 (40.8)</td><td align="left">22 (24.4)</td><td align="left">0.012</td><td align="left">71</td><td align="left">52 (49.1)</td><td align="left">19 (19.8)</td><td align="left">&#x0003c;0.0001</td></tr><tr><td align="left">&#x02003;Negative</td><td align="left">145</td><td align="left">77 (59.2)</td><td align="left">68 (75.6)</td><td></td><td align="left">131</td><td align="left">54 (50.9)</td><td align="left">77 (80.2)</td><td></td></tr><tr><td align="left">Cytokeratin 5</td><td align="left">224</td><td></td><td></td><td></td><td align="left">204</td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;Positive</td><td align="left">50</td><td align="left">36 (27.5)</td><td align="left">14 (15)</td><td align="left">0.027</td><td align="left">48</td><td align="left">39 (36.4)</td><td align="left">9 (9.3)</td><td align="left">&#x0003c;0.0001</td></tr><tr><td align="left">&#x02003;Negative</td><td align="left">174</td><td align="left">95 (72.5)</td><td align="left">79 (85)</td><td></td><td align="left">156</td><td align="left">68 (63.6)</td><td align="left">88 (90.7)</td><td></td></tr><tr><td align="left">Cytokeratin 14</td><td align="left">219</td><td></td><td></td><td></td><td align="left">201</td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;Positive</td><td align="left">14</td><td align="left">13 (10.1)</td><td align="left">1 (1.5)</td><td align="left">0.007</td><td align="left">14</td><td align="left">14 (13.3)</td><td align="left">0 (0)</td><td align="left">0.0002</td></tr><tr><td align="left">&#x02003;Negative</td><td align="left">205</td><td align="left">116 (89.9)</td><td align="left">89 (98.9)</td><td></td><td align="left">187</td><td align="left">91 (86.7)</td><td align="left">96 (100)</td><td></td></tr><tr><td align="left">Vimentin</td><td align="left">203</td><td></td><td></td><td></td><td align="left">194</td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;Positive</td><td align="left">34</td><td align="left">28 (23.1)</td><td align="left">6 (7.3)</td><td align="left">0.003</td><td align="left">32</td><td align="left">26 (25)</td><td align="left">6 (6.7)</td><td align="left">0.0006</td></tr><tr><td align="left">&#x02003;Negative</td><td align="left">169</td><td align="left">93 (76.9)</td><td align="left">76 (92.7)</td><td></td><td align="left">162</td><td align="left">78 (75)</td><td align="left">84 (93.3)</td><td></td></tr><tr><td align="left">FOXA1</td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td align="left">201</td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;Positive</td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td></td><td align="left">82</td><td align="left">16 (15.4)</td><td align="left">66 (68)</td><td align="left">&#x0003c;0.0001</td></tr><tr><td align="left">&#x02003;Negative</td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td></td><td align="left">119</td><td align="left">88 (84.6)</td><td align="left">31 (32)</td><td></td></tr><tr><td align="left">GATA-3</td><td align="left">201</td><td></td><td></td><td></td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td align="left">-</td></tr><tr><td align="left">&#x02003;Positive</td><td align="left">97</td><td align="left">31 (26.1)</td><td align="left">66 (80.5)</td><td align="left">&#x0003c;0.0001</td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td></td></tr><tr><td align="left">&#x02003;Negative</td><td align="left">104</td><td align="left">88 (73.9)</td><td align="left">16 (19.5)</td><td></td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td></td></tr><tr><td align="left">Subtype</td><td align="left">202</td><td></td><td></td><td></td><td align="left">187</td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;Luminal A</td><td align="left">125</td><td align="left">56 (47)</td><td align="left">69 (83.1)</td><td align="left">&#x0003c;0.0001</td><td align="left">114</td><td align="left">36 (36.7)</td><td align="left">78 (87.7)</td><td align="left">&#x0003c;0.0001</td></tr><tr><td align="left">&#x02003;Luminal B</td><td align="left">8</td><td align="left">4 (3.4)</td><td align="left">4 (4.8)</td><td></td><td align="left">8</td><td align="left">5 (5.1)</td><td align="left">3 (3.4)</td><td></td></tr><tr><td align="left">&#x02003;HER-2</td><td align="left">27</td><td align="left">23 (19.3)</td><td align="left">4 (4.8)</td><td></td><td align="left">26</td><td align="left">24 (24.5)</td><td align="left">2 (2.2)</td><td></td></tr><tr><td align="left">&#x02003;Basal</td><td align="left">42</td><td align="left">36 (30.3)</td><td align="left">6 (7.3)</td><td></td><td align="left">39</td><td align="left">33 (33.7)</td><td align="left">6 (6.7)</td><td></td></tr></tbody></table><table-wrap-foot><p>FOXA-1, forkhead box A1; GATA-3, GATA binding protein 3; EGFR, epidermal growth factor receptor; HER-2, human epidermal growth factor receptor 2.</p></table-wrap-foot></table-wrap><p>The immunohistochemical evaluation of FOXA1 and GATA-3 in breast tumour samples revealed that in 201 of interpretable cases a very significant direct association between the expression of FOXA1 and GATA-3 was observed (<italic>P </italic>&#x0003c; 0.0001) (Table <xref ref-type="table" rid="T3">3</xref>).</p><p>On the evaluation of these two transcription factors with other important immunohistochemical markers in breast cancer, we found a strong inverse association with basal-like phenotype markers &#x02013; namely, CK14 (<italic>P </italic>= 0.007, <italic>P </italic>= 0.0002), CK5 (<italic>P </italic>= 0.027, <italic>P </italic>&#x0003c; 0.0001), vimentin (<italic>P </italic>= 0.003, <italic>P </italic>= 0.0006) and P-cadherin (<italic>P </italic>= 0.012, <italic>P </italic>&#x0003c; 0.0001) for FOXA1 and GATA-3, respectively. GATA-3, but not FOXA1, showed an interesting inverse association with EGFR (<italic>P </italic>= 0.001) (Table <xref ref-type="table" rid="T3">3</xref>).</p></sec><sec><title>Survival and patient outcome analysis</title><p>Kaplan&#x02013;Meier survival curves demonstrate that patients with FOXA1-positive breast carcinomas showed a significant difference towards the longer disease-free survival time (<italic>P </italic>&#x0003c; 0.001; Figure <xref ref-type="fig" rid="F2">2a</xref>). Although these are no statistically significant differences in survival according to GATA-3 expression (<italic>P </italic>= 0.055; Figure <xref ref-type="fig" rid="F2">2b</xref>), the positivity for this marker is also associated with a better outcome for breast cancer patients.</p><fig position="float" id="F2"><label>Figure 2</label><caption><p>Kaplan&#x02013;Meier survival curves for disease-free survival. <bold>(a) </bold>Survival functions for forkhead box A1 (FOXA1) in the whole breast cancer patient series (<italic>P </italic>&#x0003c; 0.001). <bold>(b) </bold>Survival functions for GATA binding protein 3 (GATA-3) in the whole breast cancer patient series (<italic>P </italic>= 0.055). <bold>(c) </bold>Survival functions for FOXA1 in the oestrogen receptor &#x003b1;-negative breast cancer patient cohort (<italic>P </italic>= 0.064). <bold>(d) </bold>Survival functions for GATA-3 in the oestrogen receptor &#x003b1;-negative breast cancer patient cohort (<italic>P </italic>= 0.488).</p></caption><graphic xlink:href="bcr2327-2"/></fig><p>As previously demonstrated in other studies, univariate Cox proportional hazard analysis showed that the tumour size, lymph node stage, tumour grade, as well as the expression of ER, PR and HER-2 were significant predictors for disease-free survival. In accordance with the trend shown by the Kaplan&#x02013;Meier curves, the expression of FOXA1 was also a significant predictor for disease-free survival, showing that negative cases carry a fourfold increased risk of recurrence (hazard ratio = 4.25, 95% confidence interval = 1.76 to 10.28) when compared with the positive ones. In contrast, GATA-3 expression was revealed not to be important as a predictive marker for better outcome in this series (hazard ratio = 1.97, 95% confidence interval = 0.96 to 4.01) (Table <xref ref-type="table" rid="T4">4</xref>).</p><table-wrap position="float" id="T4"><label>Table 4</label><caption><p>Univariate Cox proportional hazard analysis (disease-free survival) in the whole breast cancer series</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left">Variable</td><td align="left">Evaluation</td><td align="left">Hazard ratio (95% confidence interval)</td><td align="left"><italic>P </italic>value</td></tr></thead><tbody><tr><td align="left">Tumour size</td><td align="left">T1 (&#x02264; 2 mm)</td><td align="left">1</td><td></td></tr><tr><td></td><td align="left">T2 (2 &#x0003c; T &#x02264; 5 mm)</td><td align="left">1.57 (0.70 to 3.51)</td><td align="left">0.265</td></tr><tr><td></td><td align="left">T3 (&#x0003e;5 mm)</td><td align="left">3.12 (1.16 to 8.41)</td><td align="left">0.024</td></tr><tr><td align="left">Lymph node stage</td><td align="left">Negative</td><td align="left">1</td><td></td></tr><tr><td></td><td align="left">1 to 3 lymph nodes</td><td align="left">0.56 (0.20 to 1.56)</td><td align="left">0.272</td></tr><tr><td></td><td align="left">&#x0003e;3 lymph nodes</td><td align="left">2.68 (1.30 to 5.49)</td><td align="left">0.007</td></tr><tr><td align="left">Tumour grade</td><td align="left">Grade I</td><td align="left">1</td><td></td></tr><tr><td></td><td align="left">Grade II</td><td align="left">2.60 (0.58 to 11.56)</td><td align="left">0.208</td></tr><tr><td></td><td align="left">Grade III</td><td align="left">7.65 (1.80 to 32.48)</td><td align="left">0.006</td></tr><tr><td align="left">ER expression</td><td align="left">ER-positive</td><td align="left">1</td><td></td></tr><tr><td></td><td align="left">ER-negative</td><td align="left">2.94 (1.52 to 5.57)</td><td align="left">0.001</td></tr><tr><td align="left">PR expression</td><td align="left">PR-positive</td><td align="left">1</td><td></td></tr><tr><td></td><td align="left">PR-negative</td><td align="left">2.16 (1.04 to 4.46)</td><td align="left">0.038</td></tr><tr><td align="left">HER-2/neu expression</td><td align="left">HER-2/neu-negative</td><td align="left">1</td><td></td></tr><tr><td></td><td align="left">HER-2/neu-positive</td><td align="left">2.47 (1.19 to 5.09)</td><td align="left">0.014</td></tr><tr><td align="left">FOXA1 expression</td><td align="left">FOXA1-positive</td><td align="left">1</td><td></td></tr><tr><td></td><td align="left">FOXA1-negative</td><td align="left">4.25 (1.76 to 10.28)</td><td align="left">0.001</td></tr><tr><td align="left">GATA-3 expression</td><td align="left">GATA-3-positive</td><td align="left">1</td><td></td></tr><tr><td></td><td align="left">GATA-3-negative</td><td align="left">1.97 (0.96 to 4.01)</td><td align="left">0.061</td></tr></tbody></table><table-wrap-foot><p>ER, oestrogen receptor; FOXA-1, forkhead box A1; GATA-3, GATA binding protein 3; HER-2, human epidermal growth factor receptor 2; PR, progesterone receptor.</p></table-wrap-foot></table-wrap></sec><sec><title>Prognostic significance of FOXA1 and GATA-3 expression in ER-negative breast cancer</title><p>Several studies have shown that FOXA1 and GATA-3 expression are strong predictors of better clinical outcome in breast tumours and are among the best predictors of ER&#x003b1;-positive status [<xref ref-type="bibr" rid="B9">9</xref>-<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B26">26</xref>,<xref ref-type="bibr" rid="B31">31</xref>,<xref ref-type="bibr" rid="B33">33</xref>,<xref ref-type="bibr" rid="B34">34</xref>]. Since FOXA1 and GATA-3 show an intrinsic high correlation between themselves and with ER&#x003b1; status, however, the prognostic and predictive value of these markers may simply reflect this high expression association. A cohort of ER&#x003b1;-negative patients was therefore studied in order to evaluate the predictive importance of FOXA1 and GATA-3 expression in this subset of breast carcinomas.</p><p>When the association analysis was performed in the subset of ER&#x003b1;-negative patients, FOXA1 and GATA-3 failed to show any significant association with the studied clinicopathological features. Analysing the association of these transcription factors with the immunohistochemical biomarkers in breast cancer, no significant associations were found concerning FOXA1 expression. GATA-3 negativity, however, showed significant association with P-cadherin and CK14 expression. Although not statistically significant, we also observed a trend towards the association of GATA-3 with the other studied basal-like phenotype markers (namely, EGFR, CK5 and vimentin), where the majority of the negative cases for GATA-3 are positive for those proteins (Table <xref ref-type="table" rid="T5">5</xref>).</p><table-wrap position="float" id="T5"><label>Table 5</label><caption><p>Association between FOXA1 and GATA3 expression, clinicopathological features and immunohistochemical markers in ER-negative cohort</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left">Variable</td><td align="left"><italic>n</italic></td><td align="left">FOXA1-negative (%)</td><td align="left">FOXA1-positive (%)</td><td align="left"><italic>P </italic>value</td><td align="left"><italic>n</italic></td><td align="left">GATA3-negative (%)</td><td align="left">GATA3-positive (%)</td><td align="left"><italic>P </italic>value</td></tr></thead><tbody><tr><td align="left">Tumour size</td><td align="left">80</td><td align="left">36.7 &#x000b1; 24.2 (65)</td><td align="left">36.6 &#x000b1; 24.8 (15)</td><td align="left">0.987</td><td align="left">74</td><td align="left">34.46 &#x000b1; 23.6 (60)</td><td align="left">43.4 &#x000b1; 27.4 (14)</td><td align="left">0.229</td></tr><tr><td align="left">Lymphovascular invasion</td><td align="left">83</td><td></td><td></td><td></td><td align="left">78</td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;Present</td><td align="left">35</td><td align="left">29 (82.8)</td><td align="left">6 (17.2)</td><td align="left">0.391</td><td align="left">35</td><td align="left">29 (82.8)</td><td align="left">6 (17.2)</td><td align="left">0.867</td></tr><tr><td align="left">&#x02003;Absent</td><td align="left">48</td><td align="left">36 (75)</td><td align="left">12 (25)</td><td></td><td align="left">43</td><td align="left">35 (81.4)</td><td align="left">8 (18.6)</td><td></td></tr><tr><td align="left">Lymph node stage</td><td align="left">83</td><td></td><td></td><td></td><td align="left">78</td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;Negative</td><td align="left">48</td><td align="left">36 (75)</td><td align="left">12 (25)</td><td align="left">0.456</td><td align="left">43</td><td align="left">35 (81.4)</td><td align="left">8 (18.6)</td><td align="left">0.609</td></tr><tr><td align="left">&#x02003;1 to 3 lymph nodes</td><td align="left">12</td><td align="left">11 (91.7)</td><td align="left">1 (8.3)</td><td></td><td align="left">12</td><td align="left">11 (91.7)</td><td align="left">1 (8.3)</td><td></td></tr><tr><td align="left">&#x02003;&#x0003e;3 lymph nodes</td><td align="left">23</td><td align="left">18 (78.3)</td><td align="left">5 (21.7)</td><td></td><td align="left">23</td><td align="left">18 (78.3)</td><td align="left">5 (21.7)</td><td></td></tr><tr><td align="left">Grade</td><td align="left">87</td><td></td><td></td><td></td><td align="left">80</td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;Grade I</td><td align="left">8</td><td align="left">6 (75)</td><td align="left">2 (25)</td><td align="left">0.166</td><td align="left">8</td><td align="left">8 (100)</td><td align="left">0 (0)</td><td align="left">0.366</td></tr><tr><td align="left">&#x02003;Grade II</td><td align="left">33</td><td align="left">23 (69.7)</td><td align="left">10 (30.3)</td><td></td><td align="left">28</td><td align="left">22 (78.6)</td><td align="left">6 (21.4)</td><td></td></tr><tr><td align="left">&#x02003;Grade III</td><td align="left">46</td><td align="left">40 (86.9)</td><td align="left">6 (13.1)</td><td></td><td align="left">44</td><td align="left">36 (81.8)</td><td align="left">8 (18.2)</td><td></td></tr><tr><td align="left">Nottingham Prognostic Index</td><td align="left">76</td><td></td><td></td><td></td><td align="left">71</td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;&#x0003c;3.4</td><td align="left">11</td><td align="left">9 (81.8)</td><td align="left">2 (18.2)</td><td align="left">0.982</td><td align="left">10</td><td align="left">9 (90)</td><td align="left">1 (10)</td><td align="left">0.615</td></tr><tr><td align="left">&#x02003;3.4 to 5.4</td><td align="left">34</td><td align="left">27 (79.4)</td><td align="left">7 (20.6)</td><td></td><td align="left">32</td><td align="left">26 (81.3)</td><td align="left">6 (18.7)</td><td></td></tr><tr><td align="left">&#x02003;&#x0003e;5.4</td><td align="left">31</td><td align="left">25 (80.6)</td><td align="left">6 (19.4)</td><td></td><td align="left">29</td><td align="left">22 (75.8)</td><td align="left">7 (24.2)</td><td></td></tr><tr><td align="left">HER-2</td><td align="left">85</td><td></td><td></td><td></td><td align="left">79</td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;Positive</td><td align="left">26</td><td align="left">23 (88.5)</td><td align="left">3 (11.5)</td><td align="left">0.254</td><td align="left">26</td><td align="left">24 (92.3)</td><td align="left">2 (7.7)</td><td align="left">0.102</td></tr><tr><td align="left">&#x02003;Negative</td><td align="left">59</td><td align="left">46 (77.9)</td><td align="left">13 (22.1)</td><td></td><td align="left">53</td><td align="left">41 (77.4)</td><td align="left">12 (22.6)</td><td></td></tr><tr><td align="left">EGFR</td><td align="left">86</td><td></td><td></td><td></td><td align="left">80</td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;Positive</td><td align="left">12</td><td align="left">10 (83.3)</td><td align="left">2 (16.7)</td><td align="left">0.771</td><td align="left">11</td><td align="left">11 (100)</td><td align="left">0 (0)</td><td align="left">0.100</td></tr><tr><td align="left">&#x02003;Negative</td><td align="left">74</td><td align="left">59 (79.7)</td><td align="left">15 (20.3)</td><td></td><td align="left">69</td><td align="left">55 (79.7)</td><td align="left">14 (20.3)</td><td></td></tr><tr><td align="left">P-cadherin</td><td align="left">87</td><td></td><td></td><td></td><td align="left">80</td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;Positive</td><td align="left">53</td><td align="left">45 (84.9)</td><td align="left">8 (15.1)</td><td align="left">0.107</td><td align="left">52</td><td align="left">47 (90.4)</td><td align="left">5 (9.6)</td><td align="left">0.011</td></tr><tr><td align="left">&#x02003;Negative</td><td align="left">34</td><td align="left">24 (70.6)</td><td align="left">10 (29.4)</td><td></td><td align="left">28</td><td align="left">19 (67.8)</td><td align="left">9 (32.2)</td><td></td></tr><tr><td align="left">Cytokeratin 5</td><td align="left">87</td><td></td><td></td><td></td><td align="left">80</td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;Positive</td><td align="left">33</td><td align="left">28 (84.8)</td><td align="left">5 (15.2)</td><td align="left">0.318</td><td align="left">32</td><td align="left">29 (90.6)</td><td align="left">3 (9.4)</td><td align="left">0.118</td></tr><tr><td align="left">&#x02003;Negative</td><td align="left">54</td><td align="left">41 (75.9)</td><td align="left">13 (24.1)</td><td></td><td align="left">48</td><td align="left">37 (77.1)</td><td align="left">11 (22.9)</td><td></td></tr><tr><td align="left">Cytokeratin 14</td><td align="left">85</td><td></td><td></td><td></td><td align="left">78</td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;Positive</td><td align="left">14</td><td align="left">13 (92.8)</td><td align="left">1 (7.2)</td><td align="left">0.188</td><td align="left">14</td><td align="left">14 (100)</td><td align="left">0 (0)</td><td align="left">0.053</td></tr><tr><td align="left">&#x02003;Negative</td><td align="left">71</td><td align="left">55 (77.5)</td><td align="left">16 (22.5)</td><td></td><td align="left">64</td><td align="left">50 (78.1)</td><td align="left">14 (21.9)</td><td></td></tr><tr><td align="left">Vimentin</td><td align="left">82</td><td></td><td></td><td></td><td align="left">75</td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;Positive</td><td align="left">27</td><td align="left">25 (92.6)</td><td align="left">2 (7.4)</td><td align="left">0.074</td><td align="left">25</td><td align="left">24 (96)</td><td align="left">1 (4)</td><td align="left">0.064</td></tr><tr><td align="left">&#x02003;Negative</td><td align="left">55</td><td align="left">42 (76.4)</td><td align="left">13 (23.6)</td><td></td><td align="left">50</td><td align="left">40 (80)</td><td align="left">10 (20)</td><td></td></tr><tr><td align="left">FOXA1</td><td align="left">-</td><td></td><td></td><td></td><td align="left">78</td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;Positive</td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td align="left">15</td><td align="left">6 (40)</td><td align="left">9 (60)</td><td align="left">&#x0003c;0.0001</td></tr><tr><td align="left">&#x02003;Negative</td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td></td><td align="left">63</td><td align="left">58 (92.1)</td><td align="left">5 (7.9)</td><td></td></tr><tr><td align="left">GATA-3</td><td align="left">78</td><td></td><td></td><td></td><td align="left">-</td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;Positive</td><td align="left">14</td><td align="left">5 (35.7)</td><td align="left">9 (64.3)</td><td align="left">&#x0003c;0.0001</td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td align="left">-</td></tr><tr><td align="left">&#x02003;Negative</td><td align="left">64</td><td align="left">58 (90.6)</td><td align="left">6 (9.4)</td><td></td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td></td></tr></tbody></table><table-wrap-foot><p>ER, oestrogen receptor; EGFR, epidermal growth factor receptor; FOXA-1, forkhead box A1; GATA-3, GATA binding protein 3; HER-2, human epidermal growth factor receptor 2.</p></table-wrap-foot></table-wrap><p>In this subset of ER&#x003b1;-negative patients, however, an association between loss of FOXA1 expression and worst disease-free survival was found (<italic>P </italic>= 0.064), in contrast with GATA-3 expression (<italic>P </italic>= 0.488) (Figure <xref ref-type="fig" rid="F2">2c</xref> and <xref ref-type="fig" rid="F2">2d</xref>, respectively). Moreover, in order to quantify the risk of these survival associations, univariate analysis was performed for FOXA1 and GATA-3 as well as for the classical prognostic factors in breast cancer. In line with the Kaplan&#x02013;Meier curves, GATA-3 negativity does not account for an increased risk of recurrence in ER&#x003b1;-negative tumours. FOXA1 expression, however, is able to stratify this relative risk among this subset of carcinomas, since its loss accounts for a 3.61-fold increased risk for breast cancer recurrence (Table <xref ref-type="table" rid="T6">6</xref>). These results suggest a protective role for this forkhead protein in this poor-outcome breast cancer subgroup.</p><table-wrap position="float" id="T6"><label>Table 6</label><caption><p>Univariate Cox proportional hazard analysis (disease-free survival) in the oestrogen-receptor-negative cohort</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left">Variable</td><td align="left">Evaluation</td><td align="left">Hazard ratio (95% confidence interval)</td><td align="left"><italic>P </italic>value</td></tr></thead><tbody><tr><td align="left">Tumour size</td><td align="left">T1 (&#x02264; 2 mm)</td><td align="left">1</td><td></td></tr><tr><td></td><td align="left">T2 (2 &#x0003c; T &#x02264; 5 mm)</td><td align="left">1.45 (0.40 to 5.21)</td><td align="left">0.567</td></tr><tr><td></td><td align="left">T3 (&#x0003e;5 mm)</td><td align="left">3.57 (0.88 to 14.4)</td><td align="left">0.073</td></tr><tr><td align="left">Lymph node stage</td><td align="left">Negative</td><td align="left">1</td><td></td></tr><tr><td></td><td align="left">1 to 3 lymph nodes</td><td align="left">0.47 (0.10 to 2.16)</td><td align="left">0.338</td></tr><tr><td></td><td align="left">&#x0003e;3 lymph nodes</td><td align="left">2.49 (1.02 to 6.03)</td><td align="left">0.044</td></tr><tr><td align="left">Tumour grade</td><td align="left">Grade I</td><td align="left"><sup>a</sup></td><td></td></tr><tr><td></td><td align="left">Grade II</td><td align="left">1</td><td></td></tr><tr><td></td><td align="left">Grade III</td><td align="left">2.85 (1.05 to 7.57)</td><td align="left">0.040</td></tr><tr><td align="left">HER-2/neu expression</td><td align="left">HER-2/neu-negative</td><td align="left">1</td><td></td></tr><tr><td></td><td align="left">HER-2/neu-positive</td><td align="left">2.04 (0.90 to 4.61)</td><td align="left">0.086</td></tr><tr><td align="left">FOXA1 expression</td><td align="left">FOXA1-positive</td><td align="left">1</td><td></td></tr><tr><td></td><td align="left">FOXA1-negative</td><td align="left">3.61 (0.83 to 15.60)</td><td align="left">0.086</td></tr><tr><td align="left">GATA-3 expression</td><td align="left">GATA-3-positive</td><td align="left">1</td><td></td></tr><tr><td></td><td align="left">GATA-3-negative</td><td align="left">1.53 (0.44 to 5.28)</td><td align="left">0.495</td></tr></tbody></table><table-wrap-foot><p>FOXA-1, forkhead box A1; GATA-3, GATA binding protein 3; HER-2, human epidermal growth factor receptor 2. <sup>a</sup>There were no oestrogen-receptor-negative cases classified as grade I among the patients with available follow-up information.</p></table-wrap-foot></table-wrap><p>Additionally, the multivariate Cox hazard analysis, with models including tumour size and lymph vascular invasion, demonstrates the independent value of FOXA1 expression as a predictor of patient outcome in ER&#x003b1;-negative tumours. FOXA1 negativity is strongly related to breast cancer recurrence, this association being very close to statistical significance (FOXA1-negative vs. FOXA1-positive: hazard ratio = 7.02, 95% confidence interval = 0.92 to 53.37; <italic>P </italic>= 0.060). This analysis also confirmed that GATA-3 expression is not an important predictor of breast cancer recurrence in ER&#x003b1;-negative carcinomas (GATA-3-negative vs. GATA-3-positive patients: hazard ratio = 1.46, 95% confidence interval = 0.40 to 5.29; <italic>P </italic>= 0.559).</p></sec></sec><sec><title>Discussion</title><p>Several studies of global gene expression revealed high levels of FOXA1 often associated with the expression of ER&#x003b1; [<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B35">35</xref>,<xref ref-type="bibr" rid="B36">36</xref>]. In addition, other gene whose expression has been highly correlated with ER&#x003b1; in breast cancer encodes the transcription factor GATA-3 [<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B26">26</xref>,<xref ref-type="bibr" rid="B27">27</xref>]. Indeed, FOXA1, GATA-3 and ER&#x003b1; form a transcriptional circuit required for growth, differentiation and hormonal dependency of the lineage of mammary luminal cells [<xref ref-type="bibr" rid="B22">22</xref>,<xref ref-type="bibr" rid="B37">37</xref>]. Previous work using immunohistochemistry has shown that the expression of FOXA1 [<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B31">31</xref>,<xref ref-type="bibr" rid="B33">33</xref>] and of GATA-3 [<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B34">34</xref>,<xref ref-type="bibr" rid="B37">37</xref>] is in close association with ER&#x003b1; expression in breast cancer, highlighting their prognostic and predictive value in this malignancy. In fact, since these three proteins are components of a transcriptional network that dictates the phenotype of hormonal-dependent breast cancer [<xref ref-type="bibr" rid="B37">37</xref>], the study of their expression would improve our understanding of the ER&#x003b1;, FOXA1 and GATA-3 relationship in breast cancer patients.</p><p>In the present study the staining pattern of FOXA1 and GATA-3 in normal breast tissue is strikingly similar to that of ER&#x003b1;, which suggests the same cellular co-localization of these three cross-functional proteins. In the studied series, the expression of FOXA1 was inversely associated with clinicopathological features &#x02013; namely, with tumour size, tumour grade, Nottingham Prognostic Index, lymph vascular invasion, lymph node stage and HER-2 overexpression &#x02013; while its expression was directly associated with ER&#x003b1;, PR and the luminal A subtype. Thorat and colleagues, in a recent published study of 139 cases, did not demonstrate a significant association with tumour size, lymph node status or HER-2 [<xref ref-type="bibr" rid="B31">31</xref>]. Moreover, these authors also found an inverse association between FOXA1 and basal-like phenotype markers (namely, CK5 and CK14). Importantly, in our study we reinforced this inverse association between FOXA1 expression and the expression of P-cadherin or vimentin.</p><p>The requirement of this forkhead for optimal expression of at least 50% of ER&#x003b1;-regulated genes and oestrogen-induced proliferation was recently described [<xref ref-type="bibr" rid="B13">13</xref>], and our and other results may just represent the strong regulatory interdependency between ER&#x003b1; and FOXA1. Since ER&#x003b1; is one of the central genes for the regulation of growth/proliferation of mammary epithelia, and for the hormone-responsive phenotype of breast tumours [<xref ref-type="bibr" rid="B9">9</xref>], FOXA1 appears an important biological-regulatory factor with prognostic consequences in this setting. In fact, in the present study, FOXA1 expression was shown to be an important predictor of disease-free survival, in addition to the robust association with clinicopathological features. Interestingly, univariate analysis showed that the evaluation of FOXA1 expression has an important value in the assessment of the prognostic risk for breast cancer patient recurrence, with a magnitude of association similar to the observed for the classical prognostic factors, such as tumour size and lymph node stage, tumour grade, and ER and HER-2 expression. This finding is in line with previously published works, where both Badve and colleagues and Habashy and colleagues also demonstrated that FOXA1 expression is able to significantly predict a better survival for breast cancer patients [<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B33">33</xref>], although the multivariate analysis showed that it is not an independent prognostic marker, exactly as shown for ER. These studies still suggest that ER&#x003b1;/FOXA1-expressing cells, after acquiring tumorigenicity, may promote selective clonal expansion, resulting in a specific subtype of breast cancer &#x02013; the luminal subtype A. Thorat and colleagues also suggested that FOXA1 immunohistochemistry may be used as a marker for tumours pertaining to luminal subtype A breast cancer, which has an exceptionally good prognosis [<xref ref-type="bibr" rid="B31">31</xref>].</p><p>In contrast to FOXA1, GATA-3 failed the association with most of the clinicopathological features &#x02013; the exception being an inverse association with HER-2 expression and tumour histological grade, although it was also directly associated with ER&#x003b1; and PR expression, as well as with tumours from the luminal A subtype. These results are partially in line with previous work from Mehra and colleagues, which found that low levels of GATA-3 expression were associated with higher tumour histological grade, positive lymph nodes, larger tumour size, negative ER expression and HER-2 overexpression [<xref ref-type="bibr" rid="B24">24</xref>]. In the present study we could not find an association between GATA-3 expression and lymph node status, in agreement with a recent cohort study from Voduc and colleagues comprising more than 3,000 invasive breast cancers [<xref ref-type="bibr" rid="B34">34</xref>]. Regarding the association between GATA-3 and ER&#x003b1;, 66% of the cases co-expressed these markers &#x02013; which is a larger percentage than those previously described by Mehra and colleagues (46%) and by Voduc and colleagues (39%) [<xref ref-type="bibr" rid="B24">24</xref>,<xref ref-type="bibr" rid="B34">34</xref>].</p><p>Through the analysis of Kaplan&#x02013;Meier survival curves it was not possible to demonstrate a significant association between GATA-3 expression and disease-free survival in this breast cancer series, which is in accordance with data from the large cohort study of Voduc and colleagues [<xref ref-type="bibr" rid="B34">34</xref>]. The univariate analysis confirmed this observation, although there is an association between the positivity for this marker and the better outcome for breast cancer patients.</p><p>Interestingly, the strength of the inverse association that was observed between GATA-3 and basal-like markers &#x02013; namely, CK5, CK14, vimentin, EGFR and P-cadherin &#x02013; suggests that GATA-3 can be important for the differentiation state of the malignant cells, where its presence, together with other differentiation involved partners, may drive the luminal profile of a malignant cell population within the tumour. Actually, this growth and differentiation role for GATA-3 in normal mammary epithelial cells has been already widely described [<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B22">22</xref>,<xref ref-type="bibr" rid="B34">34</xref>,<xref ref-type="bibr" rid="B38">38</xref>]. Moreover, GATA-3-induced genes were found in the luminal cluster of gene expression studies, highlighting its putative ability to maintain a luminal differentiated phenotype [<xref ref-type="bibr" rid="B34">34</xref>].</p><p>In the past, several studies have shown that FOXA1 expression and GATA-3 expression are among the best predictors of ER&#x003b1;-positive status [<xref ref-type="bibr" rid="B9">9</xref>-<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B26">26</xref>,<xref ref-type="bibr" rid="B31">31</xref>,<xref ref-type="bibr" rid="B33">33</xref>,<xref ref-type="bibr" rid="B34">34</xref>]. Additionally, some reports have proven that FOXA1 expression is able to significantly differentiate patients with a better survival within the luminal A subgroup, or even within the ER&#x003b1;-positive cohort (including luminal A and luminal B subtypes) [<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B31">31</xref>]. These authors claim that FOXA1 can serve as a clinical marker for the luminal A subtype, and that its prognostic ability in these low-risk breast cancers may prove to be useful in clinical treatment decisions. In contrast, Habashy and colleagues did not find any clinical relevance in the immunohistochemical assessment of FOXA1 in breast cancer routine practice [<xref ref-type="bibr" rid="B33">33</xref>], since it was not able to stratify ER-positive (luminal-like) tumours into clinically significant subgroups.</p><p>Although never assessed, the difference between these studies can be possibly due to the endocrine and chemotherapy administered to the different series of patients, which can block the ER&#x003b1;-associated pathways and confound interpretation of the results. Moreover, since ER&#x003b1;, FOXA1 and GATA-3 show an intrinsic high correlation between themselves, the prognostic and predictive values of these markers may simply reflect this high expression association and the described biological interactions.</p><p>In order to study whether there was a prognostic value for the expression of these two transcription factors in the absence of ER&#x003b1; expression, we therefore decided to perform an exploratory subgroup analysis in a cohort of ER&#x003b1;-negative patients. The aim was to test, for the first time, the possible utility of FOXA1 and/or GATA-3 as classifiers for breast cancer recurrence in this high-risk subset of patients, revealing a stratification of ER-negative tumours with different biological behaviours. Interestingly, only FOXA1-positive expression showed a clear protective effect for breast cancer relapse in this cohort of patients with poor prognosis. Patients with loss of FOXA1 tumour expression showed an increased risk for breast cancer recurrence compared with the patients that were positive for this marker. The relative risk estimate was higher than that calculated for HER-2 positivity, which is a well-known prognostic factor in hormone-independent breast carcinomas. Moreover, the multivariate analysis, including the tumour size and lymph node status, demonstrated the independent value of FOXA1 as a predictor of patient outcome in ER&#x003b1;-negative tumours.</p><p>In conclusion, our results confirmed the strong association between ER&#x003b1; and FOXA1 in breast cancer and confirmed the role of FOXA1 as a significant breast cancer predictor of good outcome in univariate analysis, directly associated with luminal A and inversely associated with basal-like subtype of breast cancer. GATA-3 was neither a predictor for breast cancer disease-free survival nor a prognostic marker, but was shown to be an important and robust luminal differentiation marker, even stronger than FOXA1. Based on these findings, the expression assessment of FOXA1 and GATA-3 in breast cancer patients can provide important clinical information &#x02013; not only regarding the favourable prognostic nature and tumour behaviour, but the expression can also constitute an important tool to define and assess the luminal A subtype in breast cancer. We demonstrated that FOXA1 expression also has an important role as breast cancer predictor of good outcome in ER-negative breast carcinomas.</p><p>Based on our results, we can consider that the expression of FOXA1, as an ER-associated gene, may be important to the hormone-responsive phenotype of breast cancer, regardless of the tumour ER status. The absence of FOXA1 in luminal/ER-positive breast cancer patients may contribute to identify the 30% of ER-positive tumours that are not hormone responsive. Additionally, because of the known cross-talk and functional network between FOXA1 and the regulation of ER&#x003b1; and its downstream targets, the expression of FOXA1 in ER-negative breast cancer patients may represent the existence of an alternative oestradiol-independent response pathway, which may allow the 5 to 15% of ER-negative tumours to become responsive to endocrine-driven therapies. The clinical implication of these findings requires a larger prospective cohort, especially to evaluate the value of FOXA1 in the therapeutic response setting. Nevertheless, the current study already represents an important step forward in the overview the ER-negative type of tumours, with putative future benefit for staging and treatment of these patients.</p></sec><sec><title>Conclusions</title><p>Current challenges in oncology include prediction of tumour behaviour and selection of effective therapy for individual treatment based on molecular targets. In breast cancer, ER&#x003b1; expression alone has been used to guide systemic therapy and to estimate patient prognosis. Not all ER-positive carcinomas, however, show comparable prognosis or react similarly to anti-hormonal therapy, and some ER-negative tumours curiously respond to therapy. This clinical evidence demonstrates that breast carcinomas are extremely heterogeneous, emphasizing the need for improving the molecular classification within tumours to better predict their clinical behaviour and the patient's response to current therapies.</p><p>The identification of transcription factors that control the ER&#x003b1; pathway provide an opportunity to identify specific subsets of patients that will have a good prognosis, as well as who will benefit from endocrine treatment. In the present work, we studied FOXA1 and GATA-3 expression in order to evaluate whether the proteins would predict the recurrence behaviour of breast cancer patients. We verified that patients harbouring FOXA1-positive and ER-negative tumours show a better disease-free survival, demonstrating the clinical importance of these two biomarkers in breast cancer molecular classification and prognosis. The analyses showed that FOXA1 and ER&#x003b1; should be used together in order to subclassify breast carcinomas and to predict the outcome of breast cancer patients.</p></sec><sec><title>Abbreviations</title><p>CK: cytokeratin; EGFR: epidermal growth factor receptor; ER: oestrogen receptor; FOXA-1: forkhead box A1; GATA-3: GATA binding protein 3; HER-2: human epidermal growth factor receptor 2; PBS: phosphate-buffered saline; P-cadherin: placental cadherin; PR: progesterone receptor.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>AA, BS, DV and NLo carried out all the immunoassays and general laboratory work. FM, VC and FS were the pathologists who revised and classified all cases. NLu, JB and SC performed the statistical analysis. AA and JP contributed to the conception and design, analysis and interpretation of data. AA, JP, FM, EWL and FS were involved in drafting the manuscript and revising it critically for important intellectual content. All authors read and approved the final manuscript.</p></sec></body><back><ack><sec><title>Acknowledgements</title><p>The present study was supported by a research grant (SFRH/BD/15316/2005 to AA) financed by the Portuguese Science and Technology Foundation (FCT). The authors thank Prof. Raquel Seruca (coordinator from the Cancer Genetics group at IPATIMUP) for scientific assistance, Dr Jos&#x000e9; Lu&#x000ed;s Costa (postdoctorate at IPATIMUP) for critically reading the manuscript before submission, and Dr Nuno Marcos (PhD student at IPATIMUP) for artwork assistance.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Knight</surname><given-names>WA</given-names><suffix>3rd</suffix></name><name><surname>Osborne</surname><given-names>CK</given-names></name><name><surname>Yochmowitz</surname><given-names>MG</given-names></name><name><surname>McGuire</surname><given-names>WL</given-names></name></person-group><article-title>Steroid hormone receptors in the management of human breast cancer</article-title><source>Ann Clin Res</source><year>1980</year><volume>12</volume><fpage>202</fpage><lpage>207</lpage><pub-id pub-id-type="pmid">7015982</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>J</given-names></name><name><surname>Ruschhaupt</surname><given-names>M</given-names></name><name><surname>Buness</surname><given-names>A</given-names></name><name><surname>Asslaber</surname><given-names>M</given-names></name><name><surname>Regitnig</surname><given-names>P</given-names></name><name><surname>Zatloukal</surname><given-names>K</given-names></name><name><surname>Schippinger</surname><given-names>W</given-names></name><name><surname>Ploner</surname><given-names>F</given-names></name><name><surname>Poustka</surname><given-names>A</given-names></name><name><surname>Sultmann</surname><given-names>H</given-names></name></person-group><article-title>Identification and meta-analysis of a small gene expression signature for the diagnosis of estrogen receptor status in invasive ductal breast cancer</article-title><source>Int J Cancer</source><year>2006</year><volume>119</volume><fpage>2974</fpage><lpage>2979</lpage><pub-id pub-id-type="pmid">17019712</pub-id><pub-id pub-id-type="doi">10.1002/ijc.22234</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jordan</surname><given-names>VC</given-names></name><name><surname>Wolf</surname><given-names>MF</given-names></name><name><surname>Mirecki</surname><given-names>DM</given-names></name><name><surname>Whitford</surname><given-names>DA</given-names></name><name><surname>Welshons</surname><given-names>WV</given-names></name></person-group><article-title>Hormone receptor assays: clinical usefulness in the management of carcinoma of the breast</article-title><source>Crit Rev Clin Lab Sci</source><year>1988</year><volume>26</volume><fpage>97</fpage><lpage>152</lpage><pub-id pub-id-type="pmid">2852576</pub-id><pub-id pub-id-type="doi">10.3109/10408368809106860</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Perou</surname><given-names>CM</given-names></name><name><surname>Sorlie</surname><given-names>T</given-names></name><name><surname>Eisen</surname><given-names>MB</given-names></name><name><surname>Rijn</surname><given-names>M van de</given-names></name><name><surname>Jeffrey</surname><given-names>SS</given-names></name><name><surname>Rees</surname><given-names>CA</given-names></name><name><surname>Pollack</surname><given-names>JR</given-names></name><name><surname>Ross</surname><given-names>DT</given-names></name><name><surname>Johnsen</surname><given-names>H</given-names></name><name><surname>Akslen</surname><given-names>LA</given-names></name><name><surname>Fluge</surname><given-names>O</given-names></name><name><surname>Pergamenschikov</surname><given-names>A</given-names></name><name><surname>Williams</surname><given-names>C</given-names></name><name><surname>Zhu</surname><given-names>SX</given-names></name><name><surname>L&#x000f8;nning</surname><given-names>PE</given-names></name><name><surname>B&#x000f8;rresen-Dale</surname><given-names>AL</given-names></name><name><surname>Brown</surname><given-names>PO</given-names></name><name><surname>Botstein</surname><given-names>D</given-names></name></person-group><article-title>Molecular portraits of human breast tumours</article-title><source>Nature</source><year>2000</year><volume>406</volume><fpage>747</fpage><lpage>752</lpage><pub-id pub-id-type="pmid">10963602</pub-id><pub-id pub-id-type="doi">10.1038/35021093</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>S&#x000f8;rlie</surname><given-names>T</given-names></name><name><surname>Perou</surname><given-names>CM</given-names></name><name><surname>Tibshirani</surname><given-names>R</given-names></name><name><surname>Aas</surname><given-names>T</given-names></name><name><surname>Geisler</surname><given-names>S</given-names></name><name><surname>Johnsen</surname><given-names>H</given-names></name><name><surname>Hastie</surname><given-names>T</given-names></name><name><surname>Eisen</surname><given-names>MB</given-names></name><name><surname>Rijn</surname><given-names>M van de</given-names></name><name><surname>Jeffrey</surname><given-names>SS</given-names></name><name><surname>Thorsen</surname><given-names>T</given-names></name><name><surname>Quist</surname><given-names>H</given-names></name><name><surname>Matese</surname><given-names>JC</given-names></name><name><surname>Brown</surname><given-names>PO</given-names></name><name><surname>Botstein</surname><given-names>D</given-names></name><name><surname>Eystein L&#x000f8;nning</surname><given-names>P</given-names></name><name><surname>B&#x000f8;rresen-Dale</surname><given-names>AL</given-names></name></person-group><article-title>Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications</article-title><source>Proc Natl Acad Sci USA</source><year>2001</year><volume>98</volume><fpage>10869</fpage><lpage>10874</lpage><pub-id pub-id-type="pmid">11553815</pub-id><pub-id pub-id-type="doi">10.1073/pnas.191367098</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vijver</surname><given-names>MJ van de</given-names></name><name><surname>He</surname><given-names>YD</given-names></name><name><surname>van't Veer</surname><given-names>LJ</given-names></name><name><surname>Dai</surname><given-names>H</given-names></name><name><surname>Hart</surname><given-names>AA</given-names></name><name><surname>Voskuil</surname><given-names>DW</given-names></name><name><surname>Schreiber</surname><given-names>GJ</given-names></name><name><surname>Peterse</surname><given-names>JL</given-names></name><name><surname>Roberts</surname><given-names>C</given-names></name><name><surname>Marton</surname><given-names>MJ</given-names></name><name><surname>Parrish</surname><given-names>M</given-names></name><name><surname>Atsma</surname><given-names>D</given-names></name><name><surname>Witteveen</surname><given-names>A</given-names></name><name><surname>Glas</surname><given-names>A</given-names></name><name><surname>Delahaye</surname><given-names>L</given-names></name><name><surname>Velde</surname><given-names>T van der</given-names></name><name><surname>Bartelink</surname><given-names>H</given-names></name><name><surname>Rodenhuis</surname><given-names>S</given-names></name><name><surname>Rutgers</surname><given-names>ET</given-names></name><name><surname>Friend</surname><given-names>SH</given-names></name><name><surname>Bernards</surname><given-names>R</given-names></name></person-group><article-title>A gene-expression signature as a predictor of survival in breast cancer</article-title><source>N Engl J Med</source><year>2002</year><volume>347</volume><fpage>1999</fpage><lpage>2009</lpage><pub-id pub-id-type="pmid">12490681</pub-id><pub-id pub-id-type="doi">10.1056/NEJMoa021967</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ramaswamy</surname><given-names>S</given-names></name><name><surname>Ross</surname><given-names>KN</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name><name><surname>Golub</surname><given-names>TR</given-names></name></person-group><article-title>A molecular signature of metastasis in primary solid tumors</article-title><source>Nat Genet</source><year>2003</year><volume>33</volume><fpage>49</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">12469122</pub-id><pub-id pub-id-type="doi">10.1038/ng1060</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weigelt</surname><given-names>B</given-names></name><name><surname>Horlings</surname><given-names>HM</given-names></name><name><surname>Kreike</surname><given-names>B</given-names></name><name><surname>Hayes</surname><given-names>MM</given-names></name><name><surname>Hauptmann</surname><given-names>M</given-names></name><name><surname>Wessels</surname><given-names>LF</given-names></name><name><surname>de Jong</surname><given-names>D</given-names></name><name><surname>Vijver</surname><given-names>MJ Van de</given-names></name><name><surname>Van't Veer</surname><given-names>LJ</given-names></name><name><surname>Peterse</surname><given-names>JL</given-names></name></person-group><article-title>Refinement of breast cancer classification by molecular characterization of histological special types</article-title><source>J Pathol</source><year>2008</year><volume>216</volume><fpage>141</fpage><lpage>150</lpage><pub-id pub-id-type="pmid">18720457</pub-id><pub-id pub-id-type="doi">10.1002/path.2407</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hoch</surname><given-names>RV</given-names></name><name><surname>Thompson</surname><given-names>DA</given-names></name><name><surname>Baker</surname><given-names>RJ</given-names></name><name><surname>Weigel</surname><given-names>RJ</given-names></name></person-group><article-title>GATA-3 is expressed in association with estrogen receptor in breast cancer</article-title><source>Int J Cancer</source><year>1999</year><volume>84</volume><fpage>122</fpage><lpage>128</lpage><pub-id pub-id-type="pmid">10096242</pub-id><pub-id pub-id-type="doi">10.1002/(SICI)1097-0215(19990420)84:2&#x0003c;122::AID-IJC5&#x0003e;3.0.CO;2-S</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Badve</surname><given-names>S</given-names></name><name><surname>Turbin</surname><given-names>D</given-names></name><name><surname>Thorat</surname><given-names>MA</given-names></name><name><surname>Morimiya</surname><given-names>A</given-names></name><name><surname>Nielsen</surname><given-names>TO</given-names></name><name><surname>Perou</surname><given-names>CM</given-names></name><name><surname>Dunn</surname><given-names>S</given-names></name><name><surname>Huntsman</surname><given-names>DG</given-names></name><name><surname>Nakshatri</surname><given-names>H</given-names></name></person-group><article-title>FOXA1 expression in breast cancer &#x02013; correlation with luminal subtype A and survival</article-title><source>Clin Cancer Res</source><year>2007</year><volume>13</volume><fpage>4415</fpage><lpage>4421</lpage><pub-id pub-id-type="pmid">17671124</pub-id><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-07-0122</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lacroix</surname><given-names>M</given-names></name><name><surname>Leclercq</surname><given-names>G</given-names></name></person-group><article-title>About GATA3, HNF3A, and XBP1, three genes co-expressed with the oestrogen receptor-alpha gene (ESR1) in breast cancer</article-title><source>Mol Cell Endocrinol</source><year>2004</year><volume>219</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">15149721</pub-id><pub-id pub-id-type="doi">10.1016/j.mce.2004.02.021</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oh</surname><given-names>DS</given-names></name><name><surname>Troester</surname><given-names>MA</given-names></name><name><surname>Usary</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>Z</given-names></name><name><surname>He</surname><given-names>X</given-names></name><name><surname>Fan</surname><given-names>C</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Carey</surname><given-names>LA</given-names></name><name><surname>Perou</surname><given-names>CM</given-names></name></person-group><article-title>Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers</article-title><source>J Clin Oncol</source><year>2006</year><volume>24</volume><fpage>1656</fpage><lpage>1664</lpage><pub-id pub-id-type="pmid">16505416</pub-id><pub-id pub-id-type="doi">10.1200/JCO.2005.03.2755</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Carroll</surname><given-names>JS</given-names></name><name><surname>Brown</surname><given-names>M</given-names></name></person-group><article-title>Estrogen receptor target gene: an evolving concept</article-title><source>Mol Endocrinol</source><year>2006</year><volume>20</volume><fpage>1707</fpage><lpage>1714</lpage><pub-id pub-id-type="pmid">16396959</pub-id><pub-id pub-id-type="doi">10.1210/me.2005-0334</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Carroll</surname><given-names>JS</given-names></name><name><surname>Liu</surname><given-names>XS</given-names></name><name><surname>Brodsky</surname><given-names>AS</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Meyer</surname><given-names>CA</given-names></name><name><surname>Szary</surname><given-names>AJ</given-names></name><name><surname>Eeckhoute</surname><given-names>J</given-names></name><name><surname>Shao</surname><given-names>W</given-names></name><name><surname>Hestermann</surname><given-names>EV</given-names></name><name><surname>Geistlinger</surname><given-names>TR</given-names></name><name><surname>Fox</surname><given-names>EA</given-names></name><name><surname>Silver</surname><given-names>PA</given-names></name><name><surname>Brown</surname><given-names>M</given-names></name></person-group><article-title>Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1</article-title><source>Cell</source><year>2005</year><volume>122</volume><fpage>33</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">16009131</pub-id><pub-id pub-id-type="doi">10.1016/j.cell.2005.05.008</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Carlsson</surname><given-names>P</given-names></name><name><surname>Mahlapuu</surname><given-names>M</given-names></name></person-group><article-title>Forkhead transcription factors: key players in development and metabolism</article-title><source>Dev Biol</source><year>2002</year><volume>250</volume><fpage>1</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">12297093</pub-id><pub-id pub-id-type="doi">10.1006/dbio.2002.0780</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kaestner</surname><given-names>KH</given-names></name></person-group><article-title>The hepatocyte nuclear factor 3 (HNF3 or FOXA) family in metabolism</article-title><source>Trends Endocrinol Metab</source><year>2000</year><volume>11</volume><fpage>281</fpage><lpage>285</lpage><pub-id pub-id-type="pmid">10920385</pub-id><pub-id pub-id-type="doi">10.1016/S1043-2760(00)00271-X</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tomaru</surname><given-names>Y</given-names></name><name><surname>Kondo</surname><given-names>S</given-names></name><name><surname>Suzuki</surname><given-names>M</given-names></name><name><surname>Hayashizaki</surname><given-names>Y</given-names></name></person-group><article-title>A comprehensive search for HNF-3&#x003b1;-regulated genes in mouse hepatoma cells by 60K cDNA microarray and chromatin immunoprecipitation/PCR analysis</article-title><source>Biochem Biophys Res Commun</source><year>2003</year><volume>310</volume><fpage>667</fpage><lpage>674</lpage><pub-id pub-id-type="pmid">14521963</pub-id><pub-id pub-id-type="doi">10.1016/j.bbrc.2003.08.148</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Laganiere</surname><given-names>J</given-names></name><name><surname>Deblois</surname><given-names>G</given-names></name><name><surname>Lefebvre</surname><given-names>C</given-names></name><name><surname>Bataille</surname><given-names>AR</given-names></name><name><surname>Robert</surname><given-names>F</given-names></name><name><surname>Giguere</surname><given-names>V</given-names></name></person-group><article-title>From the cover: location analysis of estrogen receptor alpha target promoters reveals that FOXA1 defines a domain of the estrogen response</article-title><source>Proc Natl Acad Sci USA</source><year>2005</year><volume>102</volume><fpage>11651</fpage><lpage>11656</lpage><pub-id pub-id-type="pmid">16087863</pub-id><pub-id pub-id-type="doi">10.1073/pnas.0505575102</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>YN</given-names></name><name><surname>Lee</surname><given-names>WW</given-names></name><name><surname>Wang</surname><given-names>CY</given-names></name><name><surname>Chao</surname><given-names>TH</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>JH</given-names></name></person-group><article-title>Regulatory mechanisms controlling human E-cadherin gene expression</article-title><source>Oncogene</source><year>2005</year><volume>24</volume><fpage>8277</fpage><lpage>8290</lpage><pub-id pub-id-type="pmid">16116478</pub-id><pub-id pub-id-type="doi">10.1038/sj.onc.1208991</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Williamson</surname><given-names>EA</given-names></name><name><surname>Wolf</surname><given-names>I</given-names></name><name><surname>O'Kelly</surname><given-names>J</given-names></name><name><surname>Bose</surname><given-names>S</given-names></name><name><surname>Tanosaki</surname><given-names>S</given-names></name><name><surname>Koeffler</surname><given-names>HP</given-names></name></person-group><article-title>BRCA1 and FOXA1 proteins coregulate the expression of the cell cycle-dependent kinase inhibitor p27(Kip1)</article-title><source>Oncogene</source><year>2006</year><volume>25</volume><fpage>1391</fpage><lpage>1399</lpage><pub-id pub-id-type="pmid">16331276</pub-id><pub-id pub-id-type="doi">10.1038/sj.onc.1209170</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Asselin-Labat</surname><given-names>ML</given-names></name><name><surname>Sutherland</surname><given-names>KD</given-names></name><name><surname>Barker</surname><given-names>H</given-names></name><name><surname>Thomas</surname><given-names>R</given-names></name><name><surname>Shackleton</surname><given-names>M</given-names></name><name><surname>Forrest</surname><given-names>NC</given-names></name><name><surname>Hartley</surname><given-names>L</given-names></name><name><surname>Robb</surname><given-names>L</given-names></name><name><surname>Grosveld</surname><given-names>FG</given-names></name><name><surname>Wees</surname><given-names>J van der</given-names></name><name><surname>Lindeman</surname><given-names>GJ</given-names></name><name><surname>Visvader</surname><given-names>JE</given-names></name></person-group><article-title>Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation</article-title><source>Nat Cell Biol</source><year>2007</year><volume>9</volume><fpage>201</fpage><lpage>209</lpage><pub-id pub-id-type="pmid">17187062</pub-id><pub-id pub-id-type="doi">10.1038/ncb1530</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kouros-Mehr</surname><given-names>H</given-names></name><name><surname>Slorach</surname><given-names>EM</given-names></name><name><surname>Sternlicht</surname><given-names>MD</given-names></name><name><surname>Werb</surname><given-names>Z</given-names></name></person-group><article-title>GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland</article-title><source>Cell</source><year>2006</year><volume>127</volume><fpage>1041</fpage><lpage>1055</lpage><pub-id pub-id-type="pmid">17129787</pub-id><pub-id pub-id-type="doi">10.1016/j.cell.2006.09.048</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tong</surname><given-names>Q</given-names></name><name><surname>Hotamisligil</surname><given-names>GS</given-names></name></person-group><article-title>Developmental biology: cell fate in the mammary gland</article-title><source>Nature</source><year>2007</year><volume>445</volume><fpage>724</fpage><lpage>726</lpage><pub-id pub-id-type="pmid">17301782</pub-id><pub-id pub-id-type="doi">10.1038/445724a</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mehra</surname><given-names>R</given-names></name><name><surname>Varambally</surname><given-names>S</given-names></name><name><surname>Ding</surname><given-names>L</given-names></name><name><surname>Shen</surname><given-names>R</given-names></name><name><surname>Sabel</surname><given-names>MS</given-names></name><name><surname>Ghosh</surname><given-names>D</given-names></name><name><surname>Chinnaiyan</surname><given-names>AM</given-names></name><name><surname>Kleer</surname><given-names>CG</given-names></name></person-group><article-title>Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis</article-title><source>Cancer Res</source><year>2005</year><volume>65</volume><fpage>11259</fpage><lpage>11264</lpage><pub-id pub-id-type="pmid">16357129</pub-id><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-2495</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bertucci</surname><given-names>F</given-names></name><name><surname>Houlgatte</surname><given-names>R</given-names></name><name><surname>Benziane</surname><given-names>A</given-names></name><name><surname>Granjeaud</surname><given-names>S</given-names></name><name><surname>Ad&#x000e9;la&#x000ef;de</surname><given-names>J</given-names></name><name><surname>Tagett</surname><given-names>R</given-names></name><name><surname>Loriod</surname><given-names>B</given-names></name><name><surname>Jacquemier</surname><given-names>J</given-names></name><name><surname>Viens</surname><given-names>P</given-names></name><name><surname>Jordan</surname><given-names>B</given-names></name><name><surname>Birnbaum</surname><given-names>D</given-names></name><name><surname>Nguyen</surname><given-names>C</given-names></name></person-group><article-title>Gene expression profiling of primary breast carcinomas using arrays of candidate genes</article-title><source>Hum Mol Genet</source><year>2000</year><volume>9</volume><fpage>2981</fpage><lpage>2991</lpage><pub-id pub-id-type="pmid">11115842</pub-id><pub-id pub-id-type="doi">10.1093/hmg/9.20.2981</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gruvberger</surname><given-names>S</given-names></name><name><surname>Ringner</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Panavally</surname><given-names>S</given-names></name><name><surname>Saal</surname><given-names>LH</given-names></name><name><surname>Borg</surname><given-names>A</given-names></name><name><surname>Ferno</surname><given-names>M</given-names></name><name><surname>Peterson</surname><given-names>C</given-names></name><name><surname>Meltzer</surname><given-names>PS</given-names></name></person-group><article-title>Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns</article-title><source>Cancer Res</source><year>2001</year><volume>61</volume><fpage>5979</fpage><lpage>5984</lpage><pub-id pub-id-type="pmid">11507038</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>West</surname><given-names>M</given-names></name><name><surname>Blanchette</surname><given-names>C</given-names></name><name><surname>Dressman</surname><given-names>H</given-names></name><name><surname>Huang</surname><given-names>E</given-names></name><name><surname>Ishida</surname><given-names>S</given-names></name><name><surname>Spang</surname><given-names>R</given-names></name><name><surname>Zuzan</surname><given-names>H</given-names></name><name><surname>Olson</surname><given-names>JA</given-names><suffix>Jr</suffix></name><name><surname>Marks</surname><given-names>JR</given-names></name><name><surname>Nevins</surname><given-names>JR</given-names></name></person-group><article-title>Predicting the clinical status of human breast cancer by using gene expression profiles</article-title><source>Proc Natl Acad Sci USA</source><year>2001</year><volume>98</volume><fpage>11462</fpage><lpage>11467</lpage><pub-id pub-id-type="pmid">11562467</pub-id><pub-id pub-id-type="doi">10.1073/pnas.201162998</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Matos</surname><given-names>I</given-names></name><name><surname>Dufloth</surname><given-names>R</given-names></name><name><surname>Alvarenga</surname><given-names>M</given-names></name><name><surname>Zeferino</surname><given-names>LC</given-names></name><name><surname>Schmitt</surname><given-names>F</given-names></name></person-group><article-title>p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas</article-title><source>Virchows Arch</source><year>2005</year><volume>447</volume><fpage>688</fpage><lpage>694</lpage><pub-id pub-id-type="pmid">16012853</pub-id><pub-id pub-id-type="doi">10.1007/s00428-005-0010-7</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dufloth</surname><given-names>RM</given-names></name><name><surname>Matos</surname><given-names>I</given-names></name><name><surname>Schmitt</surname><given-names>F</given-names></name><name><surname>Zeferino</surname><given-names>LC</given-names></name></person-group><article-title>Tissue microarrays for testing basal biomarkers in familial breast cancer cases</article-title><source>Sao Paulo Med J</source><year>2007</year><volume>125</volume><fpage>226</fpage><lpage>230</lpage><pub-id pub-id-type="pmid">17992394</pub-id><pub-id pub-id-type="doi">10.1590/S1516-31802007000400007</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Paredes</surname><given-names>J</given-names></name><name><surname>Lopes</surname><given-names>N</given-names></name><name><surname>Milanezi</surname><given-names>F</given-names></name><name><surname>Schmitt</surname><given-names>FC</given-names></name></person-group><article-title>P-cadherin and cytokeratin 5: useful adjunct markers to distinguish basal-like ductal carcinomas in situ</article-title><source>Virchows Arch</source><year>2007</year><volume>450</volume><fpage>73</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">17123107</pub-id><pub-id pub-id-type="doi">10.1007/s00428-006-0334-y</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thorat</surname><given-names>MA</given-names></name><name><surname>Marchio</surname><given-names>C</given-names></name><name><surname>Morimiya</surname><given-names>A</given-names></name><name><surname>Savage</surname><given-names>K</given-names></name><name><surname>Nakshatri</surname><given-names>H</given-names></name><name><surname>Reis-Filho</surname><given-names>JS</given-names></name><name><surname>Badve</surname><given-names>S</given-names></name></person-group><article-title>Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis</article-title><source>J Clin Pathol</source><year>2008</year><volume>61</volume><fpage>327</fpage><lpage>332</lpage><pub-id pub-id-type="pmid">18037662</pub-id><pub-id pub-id-type="doi">10.1136/jcp.2007.052431</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Badve</surname><given-names>S</given-names></name><name><surname>Nakshatri</surname><given-names>H</given-names></name></person-group><article-title>Oestrogen receptor-positive breast cancer: towards bridging histopathologic and molecular classifications</article-title><source>J Clin Pathol</source><year>2009</year><volume>62</volume><fpage>6</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">18794199</pub-id><pub-id pub-id-type="doi">10.1136/jcp.2008.059899</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Habashy</surname><given-names>HO</given-names></name><name><surname>Powe</surname><given-names>DG</given-names></name><name><surname>Rakha</surname><given-names>EA</given-names></name><name><surname>Ball</surname><given-names>G</given-names></name><name><surname>Paish</surname><given-names>C</given-names></name><name><surname>Gee</surname><given-names>J</given-names></name><name><surname>Nicholson</surname><given-names>RI</given-names></name><name><surname>Ellis</surname><given-names>IO</given-names></name></person-group><article-title>Forkhead-box A1 (FOXA1) expression in breast cancer and its prognostic significance</article-title><source>Eur J Cancer</source><year>2008</year><volume>44</volume><fpage>1541</fpage><lpage>1551</lpage><pub-id pub-id-type="pmid">18538561</pub-id><pub-id pub-id-type="doi">10.1016/j.ejca.2008.04.020</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Voduc</surname><given-names>D</given-names></name><name><surname>Cheang</surname><given-names>M</given-names></name><name><surname>Nielsen</surname><given-names>T</given-names></name></person-group><article-title>GATA-3 expression in breast cancer has a strong association with estrogen receptor but lacks independent prognostic value</article-title><source>Cancer Epidemiol Biomarkers Prev</source><year>2008</year><volume>17</volume><fpage>365</fpage><lpage>373</lpage><pub-id pub-id-type="pmid">18268121</pub-id><pub-id pub-id-type="doi">10.1158/1055-9965.EPI-06-1090</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Perou</surname><given-names>CM</given-names></name><name><surname>Jeffrey</surname><given-names>SS</given-names></name><name><surname>Rijn</surname><given-names>M van de</given-names></name><name><surname>Rees</surname><given-names>CA</given-names></name><name><surname>Eisen</surname><given-names>MB</given-names></name><name><surname>Ross</surname><given-names>DT</given-names></name><name><surname>Pergamenschikov</surname><given-names>A</given-names></name><name><surname>Williams</surname><given-names>CF</given-names></name><name><surname>Zhu</surname><given-names>SX</given-names></name><name><surname>Lee</surname><given-names>JC</given-names></name><name><surname>Lashkari</surname><given-names>D</given-names></name><name><surname>Shalon</surname><given-names>D</given-names></name><name><surname>Brown</surname><given-names>PO</given-names></name><name><surname>Botstein</surname><given-names>D</given-names></name></person-group><article-title>Distinctive gene expression patterns in human mammary epithelial cells and breast cancers</article-title><source>Proc Natl Acad Sci USA</source><year>1999</year><volume>96</volume><fpage>9212</fpage><lpage>9217</lpage><pub-id pub-id-type="pmid">10430922</pub-id><pub-id pub-id-type="doi">10.1073/pnas.96.16.9212</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Doane</surname><given-names>AS</given-names></name><name><surname>Danso</surname><given-names>M</given-names></name><name><surname>Lal</surname><given-names>P</given-names></name><name><surname>Donaton</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Hudis</surname><given-names>C</given-names></name><name><surname>Gerald</surname><given-names>WL</given-names></name></person-group><article-title>An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen</article-title><source>Oncogene</source><year>2006</year><volume>25</volume><fpage>3994</fpage><lpage>4008</lpage><pub-id pub-id-type="pmid">16491124</pub-id><pub-id pub-id-type="doi">10.1038/sj.onc.1209415</pub-id></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Eeckhoute</surname><given-names>J</given-names></name><name><surname>Keeton</surname><given-names>EK</given-names></name><name><surname>Lupien</surname><given-names>M</given-names></name><name><surname>Krum</surname><given-names>SA</given-names></name><name><surname>Carroll</surname><given-names>JS</given-names></name><name><surname>Brown</surname><given-names>M</given-names></name></person-group><article-title>Positive cross-regulatory loop ties GATA-3 to estrogen receptor alpha expression in breast cancer</article-title><source>Cancer Res</source><year>2007</year><volume>67</volume><fpage>6477</fpage><lpage>6483</lpage><pub-id pub-id-type="pmid">17616709</pub-id><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-07-0746</pub-id></citation></ref><ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kouros-Mehr</surname><given-names>H</given-names></name><name><surname>Kim</surname><given-names>JW</given-names></name><name><surname>Bechis</surname><given-names>SK</given-names></name><name><surname>Werb</surname><given-names>Z</given-names></name></person-group><article-title>GATA-3 and the regulation of the mammary luminal cell fate</article-title><source>Curr Opin Cell Biol</source><year>2008</year><volume>20</volume><fpage>164</fpage><lpage>170</lpage><pub-id pub-id-type="pmid">18358709</pub-id><pub-id pub-id-type="doi">10.1016/j.ceb.2008.02.003</pub-id></citation></ref></ref-list></back></article> 